{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:19:02Z","timestamp":1780391942481,"version":"3.54.1"},"reference-count":330,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03354-1","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:19:49Z","timestamp":1773177589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanocarriers, Smart Biomaterials and Emerging Therapeutics for Psoriasis: Current Progress and Future Directions"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8994-0303","authenticated-orcid":false,"given":"Noha F.","family":"Ghazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2896-2802","authenticated-orcid":false,"given":"Nada F.","family":"Abo El-Magd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7841-7218","authenticated-orcid":false,"given":"George","family":"Bebawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"3354_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76:377\u201390. https:\/\/doi.org\/10.1016\/j.jaad.2016.07.064.","journal-title":"J Am Acad Dermatol"},{"key":"3354_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. https:\/\/doi.org\/10.1136\/bmj.m1590.","journal-title":"BMJ"},{"key":"3354_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","volume":"151","author":"EA Brezinski","year":"2015","unstructured":"Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151:651\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2014.3593.","journal-title":"JAMA Dermatol"},{"key":"3354_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"key":"3354_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17010056","volume":"17","author":"Y Gao","year":"2025","unstructured":"Gao Y, Xu T, Wang Y, Hu Y, Yin S, Qin Z, et al. Pathophysiology and treatment of psoriasis: from clinical practice to basic research. Pharmaceutics. 2025;17:56. https:\/\/doi.org\/10.3390\/pharmaceutics17010056.","journal-title":"Pharmaceutics"},{"key":"3354_CR6","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s12325-020-01346-6","volume":"37","author":"W Masson","year":"2020","unstructured":"Masson W, Lobo M, Molinero G. Psoriasis and cardiovascular risk: a comprehensive review. Adv Ther. 2020;37:2017\u201333. https:\/\/doi.org\/10.1007\/s12325-020-01346-6.","journal-title":"Adv Ther"},{"key":"3354_CR7","doi-asserted-by":"publisher","first-page":"29080","DOI":"10.1039\/D1RA06087B","volume":"11","author":"UUM Nordin","year":"2021","unstructured":"Nordin UUM, Ahmad N, Salim N, Yusof NSM. Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects. RSC Adv. 2021;11:29080\u2013101. https:\/\/doi.org\/10.1039\/D1RA06087B.","journal-title":"RSC Adv"},{"key":"3354_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01655-6","volume":"8","author":"J Guo","year":"2023","unstructured":"Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023;8:437. https:\/\/doi.org\/10.1038\/s41392-023-01655-6.","journal-title":"Signal Transduct Target Ther"},{"key":"3354_CR9","doi-asserted-by":"publisher","unstructured":"Yadav K, Kumar Sahu K, Sucheta, Yadav R, Raza W, Minz S, et al. A complex molecular landscape to drug delivery concept for achieving precise therapy in psoriasis. Med Drug Discov. 2024;22:100183. \nhttps:\/\/doi.org\/10.1016\/j.medidd.2024.100183.","DOI":"10.1016\/j.medidd.2024.100183"},{"key":"3354_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/ajd.12895","volume":"60","author":"M Rademaker","year":"2019","unstructured":"Rademaker M, Agnew K, Anagnostou N, Andrews M, Armour K, Baker C, et al. Psoriasis and infection. A clinical practice narrative. Australas J Dermatol. 2019;60:91\u20138. https:\/\/doi.org\/10.1111\/ajd.12895.","journal-title":"Australas J Dermatol"},{"key":"3354_CR11","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057.","journal-title":"J Am Acad Dermatol"},{"key":"3354_CR12","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.jid.2016.04.033","volume":"136","author":"T Mabuchi","year":"2016","unstructured":"Mabuchi T, Hirayama N. Binding affinity and interaction of LL-37 with\u00a0HLA-C*06:02 in psoriasis. J Invest Dermatol. 2016;136:1901\u20133. https:\/\/doi.org\/10.1016\/j.jid.2016.04.033.","journal-title":"J Invest Dermatol"},{"key":"3354_CR13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182:840\u20138. https:\/\/doi.org\/10.1111\/bjd.18245.","journal-title":"Br J Dermatol"},{"key":"3354_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/BTT.S252578","volume":"15","author":"ND Brownstone","year":"2021","unstructured":"Brownstone ND, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, et al. Biologic treatments of psoriasis: an update for the clinician. Biologics. 2021;15:39\u201351. https:\/\/doi.org\/10.2147\/BTT.S252578.","journal-title":"Biologics"},{"key":"3354_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/ITT.S458800","volume":"13","author":"F Zhao","year":"2024","unstructured":"Zhao F, Zhao J, Wei K, Jiang P, Shi Y, Chang C, et al. Targeted siRNA Therapy for Psoriasis: Translating Preclinical Potential into Clinical Treatments. Immunotargets Ther. 2024;13:259\u201371. https:\/\/doi.org\/10.2147\/ITT.S458800.","journal-title":"Immunotargets Ther"},{"key":"3354_CR16","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2014.5451","volume":"6","author":"N Vincent","year":"2014","unstructured":"Vincent N, Ramya DD, Vedha HB. Progress in psoriasis therapy via novel drug delivery systems. Dermatol Rep. 2014;6:5451. https:\/\/doi.org\/10.4081\/dr.2014.5451.","journal-title":"Dermatol Rep"},{"key":"3354_CR17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.4103\/ijd.ijd_422_23","volume":"68","author":"SS Ahmed","year":"2023","unstructured":"Ahmed SS, Manchanda Y, De A, Das S, Kumar R. Topical therapy in psoriasis. Indian J Dermatol. 2023;68:437\u201345. https:\/\/doi.org\/10.4103\/ijd.ijd_422_23.","journal-title":"Indian J Dermatol"},{"issue":"2","key":"3354_CR18","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.2310\/7750.2009.00021","volume":"13","author":"Y Poulin","year":"2009","unstructured":"Poulin Y, Langley RG, Teixeira HD, Martel M-J, Cheung S. Biologics in the treatment of psoriasis: clinical and economic overview. J Cutan Med Surg. 2009;13(2):S49-57. https:\/\/doi.org\/10.2310\/7750.2009.00021.","journal-title":"J Cutan Med Surg"},{"key":"3354_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051690","volume":"21","author":"M Kamata","year":"2020","unstructured":"Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21:1690. https:\/\/doi.org\/10.3390\/ijms21051690.","journal-title":"Int J Mol Sci"},{"key":"3354_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2173516","volume":"34","author":"D-PD Dao","year":"2023","unstructured":"Dao D-PD, Pixley JN, Feldman SR. When should systemic biologic therapy for psoriasis be discontinued? J Dermatolog Treat. 2023;34:2173516. https:\/\/doi.org\/10.1080\/09546634.2023.2173516.","journal-title":"J Dermatolog Treat"},{"key":"3354_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.644952","volume":"12","author":"J Xie","year":"2021","unstructured":"Xie J, Huang S, Huang H, Deng X, Yue P, Lin J, et al. Advances in the application of natural products and the novel drug delivery systems for psoriasis. Front Pharmacol. 2021;12:644952. https:\/\/doi.org\/10.3389\/fphar.2021.644952.","journal-title":"Front Pharmacol"},{"key":"3354_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102364","volume":"62","author":"SL Jyothi","year":"2021","unstructured":"Jyothi SL, Krishna KL, Ameena Shirin VK, Sankar R, Pramod K, Gangadharappa HV. Drug delivery systems for the treatment of psoriasis: current status and prospects. J Drug Deliv Sci Technol. 2021;62:102364. https:\/\/doi.org\/10.1016\/j.jddst.2021.102364.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3354_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12549","volume":"30","author":"A Chiricozzi","year":"2017","unstructured":"Chiricozzi A, Pimpinelli N, Ricceri F, Bagnoni G, Bartoli L, Bellini M, et al. Treatment of psoriasis with topical agents: recommendations from a Tuscany consensus. Dermatol Ther. 2017;30:e12549. https:\/\/doi.org\/10.1111\/dth.12549.","journal-title":"Dermatol Ther"},{"key":"3354_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12728","volume":"31","author":"A Dattola","year":"2018","unstructured":"Dattola A, Silvestri M, Bennardo L, Del Duca E, Longo C, Bianchi L, et al. Update of calcineurin inhibitors to treat inverse psoriasis: a systematic review. Dermatol Ther. 2018;31:e12728. https:\/\/doi.org\/10.1111\/dth.12728.","journal-title":"Dermatol Ther"},{"key":"3354_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4103\/2229-5178.209622","volume":"8","author":"R Torsekar","year":"2017","unstructured":"Torsekar R, Gautam MM. Topical therapies in psoriasis. Indian Dermatol Online J. 2017;8:235\u201345. https:\/\/doi.org\/10.4103\/2229-5178.209622.","journal-title":"Indian Dermatol Online J"},{"key":"3354_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub5","volume":"5","author":"E Sbidian","year":"2022","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022;5:CD011535. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub5.","journal-title":"Cochrane Database Syst Rev"},{"key":"3354_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/PTT.S64950","volume":"6","author":"N Ayala-Font\u00e1nez","year":"2016","unstructured":"Ayala-Font\u00e1nez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl). 2016;6:7\u201332. https:\/\/doi.org\/10.2147\/PTT.S64950.","journal-title":"Psoriasis (Auckl)"},{"key":"3354_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10103-017-2360-1","volume":"33","author":"P Zhang","year":"2018","unstructured":"Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers Med Sci. 2018;33:173\u201380. https:\/\/doi.org\/10.1007\/s10103-017-2360-1.","journal-title":"Lasers Med Sci"},{"key":"3354_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2310\/7750.2012.11124","volume":"17","author":"T Wong","year":"2013","unstructured":"Wong T, Hsu L, Liao W. Phototherapy in psoriasis: a review of mechanisms of action. J Cutan Med Surg. 2013;17:6\u201312. https:\/\/doi.org\/10.2310\/7750.2012.11124.","journal-title":"J Cutan Med Surg"},{"key":"3354_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13040781","volume":"13","author":"Y Li","year":"2025","unstructured":"Li Y, Cheng Y, Cai Y, Duan Z, Xu H, Huang Y, et al. Novel small-molecule treatment and emerging biological therapy for psoriasis. Biomedicines. 2025;13:781. https:\/\/doi.org\/10.3390\/biomedicines13040781.","journal-title":"Biomedicines"},{"key":"3354_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12866","volume":"32","author":"M Daniyal","year":"2019","unstructured":"Daniyal M, Akram M, Zainab R, Munir N, Shah SMA, Liu B, et al. Progress and prospects in the management of psoriasis and developments in phyto-therapeutic modalities. Dermatol Ther. 2019;32:e12866. https:\/\/doi.org\/10.1111\/dth.12866.","journal-title":"Dermatol Ther"},{"key":"3354_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.biochi.2016.01.013","volume":"123","author":"D Kang","year":"2016","unstructured":"Kang D, Li B, Luo L, Jiang W, Lu Q, Rong M, et al. Curcumin shows excellent therapeutic effect on psoriasis in mouse model. Biochimie. 2016;123:73\u201380. https:\/\/doi.org\/10.1016\/j.biochi.2016.01.013.","journal-title":"Biochimie"},{"key":"3354_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118844","volume":"573","author":"M Pleguezuelos-Villa","year":"2020","unstructured":"Pleguezuelos-Villa M, Diez-Sales O, Manca ML, Manconi M, Sauri AR, Escribano-Ferrer E, et al. Mangiferin glycethosomes as a new potential adjuvant for the treatment of psoriasis. Int J Pharm. 2020;573:118844. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118844.","journal-title":"Int J Pharm"},{"key":"3354_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2019.110352","volume":"182","author":"S Meng","year":"2019","unstructured":"Meng S, Sun L, Wang L, Lin Z, Liu Z, Xi L, et al. Loading of water-insoluble celastrol into niosome hydrogels for improved topical permeation and anti-psoriasis activity. Colloids Surf B Biointerfaces. 2019;182:110352. https:\/\/doi.org\/10.1016\/j.colsurfb.2019.110352.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3354_CR35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ejps.2016.10.025","volume":"96","author":"S Doppalapudi","year":"2017","unstructured":"Doppalapudi S, Jain A, Chopra DK, Khan W. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis. Eur J Pharm Sci. 2017;96:515\u201329. https:\/\/doi.org\/10.1016\/j.ejps.2016.10.025.","journal-title":"Eur J Pharm Sci"},{"key":"3354_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.124779","volume":"242","author":"RD Herculano","year":"2023","unstructured":"Herculano RD, Dos Santos TO, de Barros NR, Pegorin Brasil GS, Scontri M, Carvalho BG, et al. Aloe vera-loaded natural rubber latex dressing as a potential complementary treatment for psoriasis. Int J Biol Macromol. 2023;242:124779. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.124779.","journal-title":"Int J Biol Macromol"},{"key":"3354_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116745","volume":"233","author":"L Xiang","year":"2025","unstructured":"Xiang L, Shen Y, Liu S, Fan B, Zhan J, Zhou Y, et al. Guggulsterone ameliorates psoriasis by inhibiting keratinocyte proliferation and inflammation through induction of miR-17 directly targeting JAK1 and STAT3. Biochem Pharmacol. 2025;233:116745. https:\/\/doi.org\/10.1016\/j.bcp.2025.116745.","journal-title":"Biochem Pharmacol"},{"key":"3354_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2025.107291","volume":"112","author":"AM Kamel","year":"2025","unstructured":"Kamel AM, El-Kamel AH, Allam EA, Bakr BA, Ashour AA. Bioactive hydrogel-based nanosponges for enhanced berberine delivery in psoriasis: targeting chemerin and MAPK pathways. J Drug Deliv Sci Technol. 2025;112:107291. https:\/\/doi.org\/10.1016\/j.jddst.2025.107291.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3354_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29061279","volume":"29","author":"L Zhang","year":"2024","unstructured":"Zhang L, Huang Z, Xuan J, Yang L, Zhao T, Peng W. Anti-psoriatic activity of black, green and white tea extracts from southeastern China. Molecules. 2024;29:1279. https:\/\/doi.org\/10.3390\/molecules29061279.","journal-title":"Molecules"},{"key":"3354_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-021-00421-z","volume":"22","author":"H Qiong","year":"2021","unstructured":"Qiong H, Han L, Zhang N, Chen H, Yan K, Zhang Z, et al. Glycyrrhizin improves the pathogenesis of psoriasis partially through IL-17A and the SIRT1-STAT3 axis. BMC Immunol. 2021;22:34. https:\/\/doi.org\/10.1186\/s12865-021-00421-z.","journal-title":"BMC Immunol"},{"key":"3354_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2329261","volume":"56","author":"C Wang","year":"2024","unstructured":"Wang C, Yang P, Wang J, Liu L, Chen J, Cai X, et al. Evidence and potential mechanism of action of indigo naturalis and its active components in the treatment of psoriasis. Ann Med. 2024;56:2329261. https:\/\/doi.org\/10.1080\/07853890.2024.2329261.","journal-title":"Ann Med"},{"key":"3354_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12111954","volume":"12","author":"M Marko","year":"2023","unstructured":"Marko M, Pawliczak R. Resveratrol and its derivatives in inflammatory skin disorders\u2014atopic dermatitis and psoriasis: a review. Antioxidants (Basel). 2023;12:1954. https:\/\/doi.org\/10.3390\/antiox12111954.","journal-title":"Antioxidants (Basel)"},{"key":"3354_CR43","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/s0190-9622(86)70201-6","volume":"15","author":"JE Bernstein","year":"1986","unstructured":"Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol. 1986;15:504\u20137. https:\/\/doi.org\/10.1016\/s0190-9622(86)70201-6.","journal-title":"J Am Acad Dermatol"},{"key":"3354_CR44","doi-asserted-by":"publisher","unstructured":"Thomas S, Yadav PK, Saw SK, Guman, Sahu U, KumarSahu J, et al. The immunosuppressive effect of boswellic acid in managing the inflammation and symptoms associated with psoriatic arthritis. South East Eur J Public Health. 2024;2359\u201370. \nhttps:\/\/doi.org\/10.70135\/seejph.vi.3116.","DOI":"10.70135\/seejph.vi.3116"},{"key":"3354_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021498","volume":"24","author":"JH Yoon","year":"2023","unstructured":"Yoon JH, Kim M-Y, Cho JY. Apigenin: a therapeutic agent for treatment of skin inflammatory diseases and cancer. Int J Mol Sci. 2023;24:1498. https:\/\/doi.org\/10.3390\/ijms24021498.","journal-title":"Int J Mol Sci"},{"key":"3354_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102558","volume":"20","author":"T-H Huang","year":"2019","unstructured":"Huang T-H, Lin C-F, Alalaiwe A, Yang S-C, Fang J-Y. Apoptotic or antiproliferative activity of natural products against keratinocytes for the treatment of psoriasis. Int J Mol Sci. 2019;20:2558. https:\/\/doi.org\/10.3390\/ijms20102558.","journal-title":"Int J Mol Sci"},{"key":"3354_CR47","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1055\/s-0042-115177","volume":"82","author":"A Herman","year":"2016","unstructured":"Herman A, Herman AP. Topically used herbal products for the treatment of psoriasis - mechanism of action, drug delivery, clinical studies. Planta Med. 2016;82:1447\u201355. https:\/\/doi.org\/10.1055\/s-0042-115177.","journal-title":"Planta Med"},{"key":"3354_CR48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4103\/picr.picr_70_24","volume":"16","author":"K Saranraj","year":"2025","unstructured":"Saranraj K, Kiran PU. Drug repurposing: clinical practices and regulatory pathways. Perspect Clin Res. 2025;16:61\u20138. https:\/\/doi.org\/10.4103\/picr.picr_70_24.","journal-title":"Perspect Clin Res"},{"key":"3354_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100041","volume":"2","author":"H Jain","year":"2021","unstructured":"Jain H, Bhat AR, Dalvi H, Godugu C, Singh SB, Srivastava S. Repurposing approved therapeutics for new indication: addressing unmet needs in psoriasis treatment. Curr Res Pharmacol Drug Discov. 2021;2:100041. https:\/\/doi.org\/10.1016\/j.crphar.2021.100041.","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"3354_CR50","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1002\/jcp.29413","volume":"235","author":"S Thatikonda","year":"2020","unstructured":"Thatikonda S, Pooladanda V, Godugu C. Repurposing an old drug for new use: niclosamide in psoriasis-like skin inflammation. J Cell Physiol. 2020;235:5270\u201383. https:\/\/doi.org\/10.1002\/jcp.29413.","journal-title":"J Cell Physiol"},{"key":"3354_CR51","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-019-1413-0","volume":"20","author":"X Yin","year":"2019","unstructured":"Yin X, Cao X, Li J, Cheng X, Cheng G, Zou M, et al. A novel surfactant-free o\/o paclitaxel ointment for the topical treatment of psoriasis. AAPS PharmSciTech. 2019;20:212. https:\/\/doi.org\/10.1208\/s12249-019-1413-0.","journal-title":"AAPS PharmSciTech"},{"key":"3354_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101691","volume":"58","author":"R Saka","year":"2020","unstructured":"Saka R, Jain H, Kommineni N, Chella N, Khan W. Enhanced penetration and improved therapeutic efficacy of bexarotene via topical liposomal gel in imiquimod induced psoriatic plaque model in BALB\/c mice. J Drug Deliv Sci Technol. 2020;58:101691. https:\/\/doi.org\/10.1016\/j.jddst.2020.101691.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3354_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118726","volume":"573","author":"S Doppalapudi","year":"2020","unstructured":"Doppalapudi S, Jain A, Khan W, Domb AJ. Fenoldopam mesylate for treating psoriasis: a new indication for an old drug. Int J Pharm. 2020;573:118726. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118726.","journal-title":"Int J Pharm"},{"key":"3354_CR54","doi-asserted-by":"publisher","unstructured":"Tsuji G, Hashimoto-Hachiya A, Yen VH, Takemura M, Yumine A, Furue K, et al. Metformin inhibits IL-1\u03b2 secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis. Cell Death Discov. 2020;6:11. https:\/\/doi.org\/10.1038\/s41420-020-0245-8.","DOI":"10.1038\/s41420-020-0245-8"},{"key":"3354_CR55","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4314\/njm.v19i1.54216","volume":"19","author":"M Naseri","year":"2010","unstructured":"Naseri M, Hadipour A, Sepaskhah M, Namazi MR. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. Niger J Med. 2010;19:58\u201361. https:\/\/doi.org\/10.4314\/njm.v19i1.54216.","journal-title":"Niger J Med"},{"key":"3354_CR56","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/09546630510043202","volume":"16","author":"E Papakostantinou","year":"2005","unstructured":"Papakostantinou E, Xenos K, Markantonis SL, Druska S, Stratigos A, Katsambas A. Efficacy of 2 weeks\u2019 application of theophylline ointment in psoriasis vulgaris. J Dermatolog Treat. 2005;16:169\u201370. https:\/\/doi.org\/10.1080\/09546630510043202.","journal-title":"J Dermatolog Treat"},{"key":"3354_CR57","doi-asserted-by":"publisher","unstructured":"S S, S T, V P, Vs C, C G. Protective effects of ambroxol in psoriasis like skin inflammation: Exploration of possible mechanisms. International immunopharmacology. Int Immunopharmacol, 2019 [cited 2025 Sept 26];71. \nhttps:\/\/doi.org\/10.1016\/j.intimp.2019.03.035.","DOI":"10.1016\/j.intimp.2019.03.035"},{"key":"3354_CR58","doi-asserted-by":"publisher","unstructured":"Winge MCG, Nasrallah M, Jackrazi LV, Guo KQ, Fuhriman JM, Szafran R, et al. Repurposing an epithelial sodium channel inhibitor as a therapy for murine and human skin inflammation. Sci Transl Med. 2024;16:eade5915. https:\/\/doi.org\/10.1126\/scitranslmed.ade5915.","DOI":"10.1126\/scitranslmed.ade5915"},{"key":"3354_CR59","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jid.2025.02.137","volume":"145","author":"JY Lee","year":"2025","unstructured":"Lee JY, Kim HE, Lee ST, Park J, Nam K-H, Park J-Y, et al. The repurposing of nitazoxanide for psoriasis treatment exerts therapeutic effects through skin metabolic reprogramming. J Invest Dermatol. 2025;145:2495-2509.e6. https:\/\/doi.org\/10.1016\/j.jid.2025.02.137.","journal-title":"J Invest Dermatol"},{"key":"3354_CR60","first-page":"1228","volume":"9","author":"AN Geria","year":"2008","unstructured":"Geria AN, Scheinfeld NS. Talarozole, a selective inhibitor of P450-mediated all-trans retinoic acid for the treatment of psoriasis and acne. Curr Opin Investig Drugs. 2008;9:1228\u201337.","journal-title":"Curr Opin Investig Drugs"},{"key":"3354_CR61","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-025-10079-6","author":"F Cherchi","year":"2025","unstructured":"Cherchi F, Coppi E. A new approach to psoriasis therapy: photoswitchable A3 adenosine receptor activation. Purinergic Signal. 2025. https:\/\/doi.org\/10.1007\/s11302-025-10079-6.","journal-title":"Purinergic Signal"},{"key":"3354_CR62","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","volume":"161","author":"CH Smith","year":"2009","unstructured":"Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJG, Chandler DA, et al. British Association of Dermatologists\u2019 guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:987\u20131019. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09505.x.","journal-title":"Br J Dermatol"},{"key":"3354_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112297","author":"K R\u00f8nholt","year":"2017","unstructured":"R\u00f8nholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18112297.","journal-title":"Int J Mol Sci"},{"key":"3354_CR64","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8668-1","author":"C Conrad","year":"2018","unstructured":"Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol. 2018. https:\/\/doi.org\/10.1007\/s12016-018-8668-1.","journal-title":"Clin Rev Allergy Immunol"},{"key":"3354_CR65","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3109\/09546634.2015.1054782","volume":"2015","author":"PK Patel","year":"2015","unstructured":"Patel PK, King CR, Feldman SR. Biologics and biosimilars. J Dermatolog Treat. 2015;2015:299\u2013302. https:\/\/doi.org\/10.3109\/09546634.2015.1054782.","journal-title":"J Dermatolog Treat"},{"key":"3354_CR66","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","volume":"362","author":"CEM Griffiths","year":"2010","unstructured":"Griffiths CEM, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118\u201328. https:\/\/doi.org\/10.1056\/NEJMoa0810652.","journal-title":"N Engl J Med"},{"key":"3354_CR67","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01476-3","author":"HA Blair","year":"2021","unstructured":"Blair HA. Secukinumab: a review in psoriatic arthritis. Drugs. 2021. https:\/\/doi.org\/10.1007\/s40265-021-01476-3.","journal-title":"Drugs"},{"key":"3354_CR68","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0579-y","author":"A Markham","year":"2016","unstructured":"Markham A. Ixekizumab: first global approval. Drugs. 2016. https:\/\/doi.org\/10.1007\/s40265-016-0579-y.","journal-title":"Drugs"},{"key":"3354_CR69","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-025-07374-3","author":"C Li","year":"2025","unstructured":"Li C, Sun Z. Role of mirnas in the pathogenesis of psoriasis and psoriatic arthritis: a genome-wide Mendelian randomization study. Clin Rheumatol. 2025. https:\/\/doi.org\/10.1007\/s10067-025-07374-3.","journal-title":"Clin Rheumatol"},{"key":"3354_CR70","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ymthe.2024.01.005","volume":"2024","author":"M Moazzam","year":"2024","unstructured":"Moazzam M, Zhang M, Hussain A, Yu X, Huang J, Huang Y. The landscape of nanoparticle-based siRNA delivery and therapeutic development. Mol Ther. 2024;2024:284\u2013312. https:\/\/doi.org\/10.1016\/j.ymthe.2024.01.005.","journal-title":"Mol Ther"},{"key":"3354_CR71","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13290","volume":"55","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Wang P, Chen X-Y, Yan B-X, Landeck L, Wang Z-Y, et al. Sprouty1 exerts a preventive effect on the initiation of psoriasis by inhibiting innate immune antimicrobial peptide cathelicidin and immunocytes. Cell Prolif. 2022;55:e13290. https:\/\/doi.org\/10.1111\/cpr.13290.","journal-title":"Cell Prolif"},{"key":"3354_CR72","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1002\/adhm.201600418","volume":"5","author":"W Ho","year":"2016","unstructured":"Ho W, Zhang X-Q, Xu X. Biomaterials in siRNA delivery: a comprehensive review. Adv Healthc Mater. 2016;5:2715\u201331. https:\/\/doi.org\/10.1002\/adhm.201600418.","journal-title":"Adv Healthc Mater"},{"key":"3354_CR73","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/JID.2015.409","volume":"136","author":"JE Hawkes","year":"2016","unstructured":"Hawkes JE, Nguyen GH, Fujita M, Florell SR, Callis Duffin K, Krueger GG, et al. MicroRNAs in psoriasis. J Invest Dermatol. 2016;136:365\u201371. https:\/\/doi.org\/10.1038\/JID.2015.409.","journal-title":"J Invest Dermatol"},{"key":"3354_CR74","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s10753-024-01995-7","volume":"47","author":"R Wang","year":"2024","unstructured":"Wang R, Huang Y, Shao K, Yan J, Sun Q. High expression of miR-6785-5p in the serum exosomes of psoriasis patients alleviates psoriasis-like skin damage by interfering with the MNK2\/p-eIF4E axis in keratinocytes. Inflammation. 2024;47:1585\u201399. https:\/\/doi.org\/10.1007\/s10753-024-01995-7.","journal-title":"Inflammation"},{"key":"3354_CR75","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.2147\/IJN.S441353","volume":"19","author":"Y Han","year":"2024","unstructured":"Han Y, Xi L, Leng F, Xu C, Zheng Y. Topical delivery of microRNA-125b by framework nucleic acids for psoriasis treatment. Int J Nanomedicine. 2024;19:2625\u201338. https:\/\/doi.org\/10.2147\/IJN.S441353.","journal-title":"Int J Nanomedicine"},{"key":"3354_CR76","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19:673\u201394. https:\/\/doi.org\/10.1038\/s41573-020-0075-7.","journal-title":"Nat Rev Drug Discov"},{"key":"3354_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120601","volume":"602","author":"T Fukuta","year":"2021","unstructured":"Fukuta T, Tanaka D, Inoue S, Michiue K, Kogure K. Overcoming thickened pathological skin in psoriasis via iontophoresis combined with tight junction-opening peptide AT1002 for intradermal delivery of NF-\u03baB decoy oligodeoxynucleotide. Int J Pharm. 2021;602:120601. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120601.","journal-title":"Int J Pharm"},{"key":"3354_CR78","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrd.2016.199","volume":"16","author":"J Zhou","year":"2017","unstructured":"Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2017;16:181\u2013202. https:\/\/doi.org\/10.1038\/nrd.2016.199.","journal-title":"Nat Rev Drug Discov"},{"key":"3354_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108963","volume":"110","author":"SS Shobeiri","year":"2022","unstructured":"Shobeiri SS, Rezaee M, Pordel S, Haghnnavaz N, Dashti M, Moghadam M, et al. Anti-IL-17A ssDNA aptamer ameliorated psoriasis skin lesions in the imiquimod-induced psoriasis mouse model. Int Immunopharmacol. 2022;110:108963. https:\/\/doi.org\/10.1016\/j.intimp.2022.108963.","journal-title":"Int Immunopharmacol"},{"key":"3354_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.842813","volume":"10","author":"W Zhang","year":"2022","unstructured":"Zhang W, Lin J, Shi P, Su D, Cheng X, Yi W, et al. Small extracellular vesicles derived from MSCs have immunomodulatory effects to enhance delivery of ASO-210 for psoriasis treatment. Front Cell Dev Biol. 2022;10:842813. https:\/\/doi.org\/10.3389\/fcell.2022.842813.","journal-title":"Front Cell Dev Biol"},{"key":"3354_CR81","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jconrel.2015.12.042","volume":"240","author":"B Corradetti","year":"2016","unstructured":"Corradetti B, Ferrari M. Nanotechnology for mesenchymal stem cell therapies. J Control Release. 2016;240:242\u201350. https:\/\/doi.org\/10.1016\/j.jconrel.2015.12.042.","journal-title":"J Control Release"},{"key":"3354_CR82","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s10753-023-01785-7","volume":"46","author":"X Ren","year":"2023","unstructured":"Ren X, Zhong W, Li W, Tang M, Zhang K, Zhou F, et al. Human umbilical cord-derived mesenchymal stem cells alleviate psoriasis through TNF-\u03b1\/NF-\u03baB\/MMP13 pathway. Inflammation. 2023;46:987\u20131001. https:\/\/doi.org\/10.1007\/s10753-023-01785-7.","journal-title":"Inflammation"},{"key":"3354_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210132","volume":"24","author":"N Cuesta-Gomez","year":"2023","unstructured":"Cuesta-Gomez N, Medina-Ruiz L, Graham GJ, Campbell JDM. IL-6 and TGF-\u03b2-secreting adoptively-transferred murine mesenchymal stromal cells accelerate healing of psoriasis-like skin inflammation and upregulate IL-17A and TGF-\u03b2. Int J Mol Sci. 2023;24:10132. https:\/\/doi.org\/10.3390\/ijms241210132.","journal-title":"Int J Mol Sci"},{"key":"3354_CR84","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg6007","volume":"9","author":"W Zhang","year":"2023","unstructured":"Zhang W, Chen Y, Zhao Z, Zheng H, Wang S, Liao Z, et al. Adoptive Treg therapy with metabolic intervention via perforated microneedles ameliorates psoriasis syndrome. Sci Adv. 2023;9:eadg6007. https:\/\/doi.org\/10.1126\/sciadv.adg6007.","journal-title":"Sci Adv"},{"key":"3354_CR85","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/path.4786","volume":"240","author":"R Leite Dantas","year":"2016","unstructured":"Leite Dantas R, Masemann D, Schied T, Bergmeier V, Vogl T, Loser K, et al. Macrophage-mediated psoriasis can be suppressed by regulatory T lymphocytes. J Pathol. 2016;240:366\u201377. https:\/\/doi.org\/10.1002\/path.4786.","journal-title":"J Pathol"},{"key":"3354_CR86","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1089\/scd.2019.0150","volume":"29","author":"G Ali","year":"2020","unstructured":"Ali G, Elsayed AK, Nandakumar M, Bashir M, Younis I, Abu Aqel Y, et al. Keratinocytes derived from patient-specific induced pluripotent stem cells recapitulate the genetic signature of psoriasis disease. Stem Cells Dev. 2020;29:383\u2013400. https:\/\/doi.org\/10.1089\/scd.2019.0150.","journal-title":"Stem Cells Dev"},{"key":"3354_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2023.103251","volume":"73","author":"E Dev","year":"2023","unstructured":"Dev E, Adamska P, Wolnik J, Oleksy A, Pi\u0119towska Z, Zalewski A, et al. Generation of two induced pluripotent stem cell lines from psoriatic patient with cardiovascular comorbidity. Stem Cell Res. 2023;73:103251. https:\/\/doi.org\/10.1016\/j.scr.2023.103251.","journal-title":"Stem Cell Res"},{"key":"3354_CR88","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev-bioeng-071813-105108","volume":"16","author":"KK Hirschi","year":"2014","unstructured":"Hirschi KK, Li S, Roy K. Induced pluripotent stem cells for regenerative medicine. Annu Rev Biomed Eng. 2014;16:277. https:\/\/doi.org\/10.1146\/annurev-bioeng-071813-105108.","journal-title":"Annu Rev Biomed Eng"},{"key":"3354_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020287","volume":"10","author":"M Arjomandnejad","year":"2022","unstructured":"Arjomandnejad M, Kopec AL, Keeler AM. CAR-T regulatory (CAR-Treg) cells: engineering and applications. Biomedicines. 2022;10:287. https:\/\/doi.org\/10.3390\/biomedicines10020287.","journal-title":"Biomedicines"},{"key":"3354_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1418768","volume":"15","author":"S Wang","year":"2024","unstructured":"Wang S, An W, Wang Z, Wang W, Zhang B, Xu K, et al. Incidentally cured psoriasis in a patient with refractory\/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: a case report. Front Immunol. 2024;15:1418768. https:\/\/doi.org\/10.3389\/fimmu.2024.1418768.","journal-title":"Front Immunol"},{"key":"3354_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186604","volume":"21","author":"Y Sato","year":"2020","unstructured":"Sato Y, Ogawa E, Okuyama R. Role of innate immune cells in psoriasis. Int J Mol Sci. 2020;21:6604. https:\/\/doi.org\/10.3390\/ijms21186604.","journal-title":"Int J Mol Sci"},{"key":"3354_CR92","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clim.2015.10.004","volume":"177","author":"SE Dunphy","year":"2017","unstructured":"Dunphy SE, Sweeney CM, Kelly G, Tobin AM, Kirby B, Gardiner CM. Natural killer cells from psoriasis vulgaris patients have reduced levels of cytotoxicity associated degranulation and cytokine production. Clin Immunol. 2017;177:43\u20139. https:\/\/doi.org\/10.1016\/j.clim.2015.10.004.","journal-title":"Clin Immunol"},{"key":"3354_CR93","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1080\/17425247.2016.1188801","volume":"13","author":"MB Hoffman","year":"2016","unstructured":"Hoffman MB, Hill D, Feldman SR. Current challenges and emerging drug delivery strategies for the treatment of psoriasis. Expert Opin Drug Deliv. 2016;13:1461\u201373. https:\/\/doi.org\/10.1080\/17425247.2016.1188801.","journal-title":"Expert Opin Drug Deliv"},{"key":"3354_CR94","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s13311-017-0565-4","volume":"14","author":"BZ Chaudhry","year":"2017","unstructured":"Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics. 2017;14:859\u201373. https:\/\/doi.org\/10.1007\/s13311-017-0565-4.","journal-title":"Neurotherapeutics"},{"key":"3354_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.727531","volume":"9","author":"S Zhu","year":"2021","unstructured":"Zhu S, Gokhale S, Jung J, Spirollari E, Tsai J, Arceo J, et al. Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets \u2013 beyond B lymphocytes. Front Cell Dev Biol. 2021;9:727531. https:\/\/doi.org\/10.3389\/fcell.2021.727531.","journal-title":"Front Cell Dev Biol"},{"key":"3354_CR96","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70256","volume":"15","author":"Z Fang","year":"2025","unstructured":"Fang Z, Jiang R, Wang Y, Chen W, Chen X, Yin M. Topical TYK2 inhibitor ameliorates psoriasis\u2010like dermatitis via the AKT\u2010SP1\u2010NGFR\u2010AP1 pathway in keratinocytes. Clin Transl Med. 2025;15:e70256. https:\/\/doi.org\/10.1002\/ctm2.70256.","journal-title":"Clin Transl Med"},{"key":"3354_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01048","volume":"9","author":"H Li","year":"2018","unstructured":"Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048. https:\/\/doi.org\/10.3389\/fphar.2018.01048.","journal-title":"Front Pharmacol"},{"key":"3354_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/jfb14010019","volume":"14","author":"MZ Ahmad","year":"2022","unstructured":"Ahmad MZ, Mohammed AA, Algahtani MS, Mishra A, Ahmad J. Nanoscale topical pharmacotherapy in management of psoriasis: contemporary research and scope. J Funct Biomater. 2022;14:19. https:\/\/doi.org\/10.3390\/jfb14010019.","journal-title":"J Funct Biomater"},{"key":"3354_CR99","doi-asserted-by":"publisher","unstructured":"Modarresi Chahardehi A, Ojaghi HR, Motedayyen H, Arefnezhad R. Nano-based formulations of thymoquinone are new approaches for psoriasis treatment: a literature review. Front Immunol. Frontiers, 2024 [cited 2025 Sept 14];15. \nhttps:\/\/doi.org\/10.3389\/fimmu.2024.1416842.","DOI":"10.3389\/fimmu.2024.1416842"},{"key":"3354_CR100","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2174\/1871530320666200604162258","volume":"21","author":"AK Ramanunny","year":"2021","unstructured":"Ramanunny AK, Wadhwa S, Thakur D, Singh SK, Kumar R. Treatment modalities of psoriasis: a focus on requisite for topical nanocarrier. Endocr Metab Immune Disord Drug Targets. 2021;21:418\u201333. https:\/\/doi.org\/10.2174\/1871530320666200604162258.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"3354_CR101","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.addr.2019.07.010","volume":"144","author":"J Majumder","year":"2019","unstructured":"Majumder J, Taratula O, Minko T. Nanocarrier-based systems for targeted and site specific therapeutic delivery. Adv Drug Deliv Rev. 2019;144:57\u201377. https:\/\/doi.org\/10.1016\/j.addr.2019.07.010.","journal-title":"Adv Drug Deliv Rev"},{"key":"3354_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10020057","volume":"10","author":"M Danaei","year":"2018","unstructured":"Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10:57. https:\/\/doi.org\/10.3390\/pharmaceutics10020057.","journal-title":"Pharmaceutics"},{"key":"3354_CR103","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2174\/1389200218666170222145240","volume":"18","author":"S Gungor","year":"2017","unstructured":"Gungor S, Rezigue M. Nanocarriers mediated topical drug delivery for psoriasis treatment. Curr Drug Metab. 2017;18:454\u201368. https:\/\/doi.org\/10.2174\/1389200218666170222145240.","journal-title":"Curr Drug Metab"},{"key":"3354_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122938","volume":"638","author":"S Aziz Hazari","year":"2023","unstructured":"Aziz Hazari S, Kaur H, Karwasra R, Abourehab MAS, Ali Khan A, Kesharwani P. An overview of topical lipid-based and polymer-based nanocarriers for treatment of psoriasis. Int J Pharm. 2023;638:122938. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122938.","journal-title":"Int J Pharm"},{"key":"3354_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122535","volume":"631","author":"GS Gomes","year":"2023","unstructured":"Gomes GS, Frank LA, Contri RV, Longhi MS, Pohlmann AR, Guterres SS. Nanotechnology-based alternatives for the topical delivery of immunosuppressive agents in psoriasis. Int J Pharm. 2023;631:122535. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122535.","journal-title":"Int J Pharm"},{"key":"3354_CR106","doi-asserted-by":"publisher","first-page":"220","DOI":"10.2174\/1872210517666230201103935","volume":"18","author":"P Singh Patel","year":"2024","unstructured":"Singh Patel P, Srivastava R, Panchawat S. Role of apoptotic-targeted phytoconstitutent-loaded antipsoriatic nanobiocomposites. Recent Pat Nanotechnol. 2024;18:220\u201336. https:\/\/doi.org\/10.2174\/1872210517666230201103935.","journal-title":"Recent Pat Nanotechnol"},{"key":"3354_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118623","volume":"569","author":"M Bahramizadeh","year":"2019","unstructured":"Bahramizadeh M, Bahramizadeh M, Kiafar B, Jafarian AH, Nikpoor AR, Hatamipour M, et al. Development, characterization and evaluation of topical methotrexate-entrapped deformable liposome on imiquimod-induced psoriasis in a mouse model. Int J Pharm. 2019;569:118623. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118623.","journal-title":"Int J Pharm"},{"key":"3354_CR108","doi-asserted-by":"publisher","first-page":"825","DOI":"10.3109\/21691401.2014.984301","volume":"44","author":"R Gupta","year":"2016","unstructured":"Gupta R, Gupta M, Mangal S, Agrawal U, Vyas SP. Capsaicin-loaded vesicular systems designed for enhancing localized delivery for psoriasis therapy. Artif Cells Nanomed Biotechnol. 2016;44:825\u201334. https:\/\/doi.org\/10.3109\/21691401.2014.984301.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"3354_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s40199-016-0142-0","volume":"24","author":"N Bavarsad","year":"2016","unstructured":"Bavarsad N, Akhgari A, Seifmanesh S, Salimi A, Rezaie A. Statistical optimization of tretinoin-loaded penetration-enhancer vesicles (PEV) for topical delivery. DARU J Pharm Sci. 2016;24:7. https:\/\/doi.org\/10.1186\/s40199-016-0142-0.","journal-title":"DARU J Pharm Sci"},{"key":"3354_CR110","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/08982104.2019.1593449","volume":"30","author":"M Walunj","year":"2020","unstructured":"Walunj M, Doppalapudi S, Bulbake U, Khan W. Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis. J Liposome Res. 2020;30:68\u201379. https:\/\/doi.org\/10.1080\/08982104.2019.1593449.","journal-title":"J Liposome Res"},{"key":"3354_CR111","doi-asserted-by":"publisher","unstructured":"Kumar R, Dogra S, Amarji B, Singh B, Kumar S, Sharma null, et al. Efficacy of novel topical liposomal formulation of cyclosporine in mild to moderate stable plaque psoriasis: a randomized clinical trial. JAMA Dermatol. 2016;152:807\u201315. \nhttps:\/\/doi.org\/10.1001\/jamadermatol.2016.0859.","DOI":"10.1001\/jamadermatol.2016.0859"},{"key":"3354_CR112","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3109\/10717544.2015.1110845","volume":"23","author":"S Wadhwa","year":"2016","unstructured":"Wadhwa S, Singh B, Sharma G, Raza K, Katare OP. Liposomal fusidic acid as a potential delivery system: a new paradigm in the treatment of chronic plaque psoriasis. Drug Deliv. 2016;23:1204\u201313. https:\/\/doi.org\/10.3109\/10717544.2015.1110845.","journal-title":"Drug Deliv"},{"key":"3354_CR113","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-020-00635-0","volume":"18","author":"W Wang","year":"2020","unstructured":"Wang W, Shu G-F, Lu K-J, Xu X-L, Sun M-C, Qi J, et al. Flexible liposomal gel dual-loaded with all-trans retinoic acid and betamethasone for enhanced therapeutic efficiency of psoriasis. J Nanobiotechnology. 2020;18:80. https:\/\/doi.org\/10.1186\/s12951-020-00635-0.","journal-title":"J Nanobiotechnology"},{"key":"3354_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12050446","volume":"12","author":"D Fathalla","year":"2020","unstructured":"Fathalla D, Youssef EMK, Soliman GM. Liposomal and ethosomal gels for the topical delivery of anthralin: preparation, comparative evaluation and clinical assessment in psoriatic patients. Pharmaceutics. 2020;12:446. https:\/\/doi.org\/10.3390\/pharmaceutics12050446.","journal-title":"Pharmaceutics"},{"key":"3354_CR115","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1039\/D1TB00557J","volume":"9","author":"F Yu","year":"2021","unstructured":"Yu F, Zhang Y, Yang C, Li F, Qiu B, Ding W. Enhanced transdermal efficiency of curcumin-loaded peptide-modified liposomes for highly effective antipsoriatic therapy. J Mater Chem B. 2021;9:4846\u201356. https:\/\/doi.org\/10.1039\/D1TB00557J.","journal-title":"J Mater Chem B"},{"key":"3354_CR116","doi-asserted-by":"publisher","unstructured":"Reddy KR, Satyanarayana SV, Reddy VJ. Development and evaluation of clobetasol\u2013loaded solid lipid nanoparticles for topical treatment of psoriasis. Int J Appl Pharm. 2019;143\u201350. \nhttps:\/\/doi.org\/10.22159\/ijap.2019v11i5.33592.","DOI":"10.22159\/ijap.2019v11i5.33592"},{"key":"3354_CR117","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4103\/2230-973X.133047","volume":"4","author":"JR Madan","year":"2014","unstructured":"Madan JR, Khude PA, Dua K. Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery. Int J Pharm Investig. 2014;4:60\u20134. https:\/\/doi.org\/10.4103\/2230-973X.133047.","journal-title":"Int J Pharm Investig"},{"key":"3354_CR118","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijpharm.2013.08.019","volume":"456","author":"K Raza","year":"2013","unstructured":"Raza K, Singh B, Lohan S, Sharma G, Negi P, Yachha Y, et al. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm. 2013;456:65\u201372. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.08.019.","journal-title":"Int J Pharm"},{"key":"3354_CR119","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3109\/21691401.2013.832683","volume":"43","author":"U Agrawal","year":"2015","unstructured":"Agrawal U, Gupta M, Vyas SP. Capsaicin delivery into the skin with lipidic nanoparticles for the treatment of psoriasis. Artif Cells Nanomed Biotechnol. 2015;43:33\u20139. https:\/\/doi.org\/10.3109\/21691401.2013.832683.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"3354_CR120","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3109\/21691401.2014.955105","volume":"44","author":"M Pradhan","year":"2016","unstructured":"Pradhan M, Singh D, Singh MR. Influence of selected variables on fabrication of triamcinolone acetonide loaded solid lipid nanoparticles for topical treatment of dermal disorders. Artif Cells Nanomed Biotechnol. 2016;44:392\u2013400. https:\/\/doi.org\/10.3109\/21691401.2014.955105.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"3354_CR121","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/17425247.2017.1264386","volume":"14","author":"R Arora","year":"2017","unstructured":"Arora R, Katiyar SS, Kushwah V, Jain S. Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics in treatment of psoriasis: a comparative study. Expert Opin Drug Deliv. 2017;14:165\u201377. https:\/\/doi.org\/10.1080\/17425247.2017.1264386.","journal-title":"Expert Opin Drug Deliv"},{"key":"3354_CR122","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.ejpb.2008.05.008","volume":"70","author":"J-Y Fang","year":"2008","unstructured":"Fang J-Y, Fang C-L, Liu C-H, Su Y-H. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008;70:633\u201340. https:\/\/doi.org\/10.1016\/j.ejpb.2008.05.008.","journal-title":"Eur J Pharm Biopharm"},{"key":"3354_CR123","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1517\/17425247.2014.938634","volume":"11","author":"R Sonawane","year":"2014","unstructured":"Sonawane R, Harde H, Katariya M, Agrawal S, Jain S. Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis. Expert Opin Drug Deliv. 2014;11:1833\u201347. https:\/\/doi.org\/10.1517\/17425247.2014.938634.","journal-title":"Expert Opin Drug Deliv"},{"key":"3354_CR124","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.2147\/IJN.S247007","volume":"15","author":"YO Agrawal","year":"2020","unstructured":"Agrawal YO, Mahajan UB, Mahajan HS, Ojha S. Methotrexate-loaded nanostructured lipid carrier gel alleviates imiquimod-induced psoriasis by moderating inflammation: formulation, optimization, characterization, in-vitro and in-vivo studies. Int J Nanomedicine. 2020;15:4763\u201378. https:\/\/doi.org\/10.2147\/IJN.S247007.","journal-title":"Int J Nanomedicine"},{"key":"3354_CR125","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ijpharm.2014.10.067","volume":"477","author":"MF Pinto","year":"2014","unstructured":"Pinto MF, Moura CC, Nunes C, Segundo MA, Costa Lima SA, Reis S. A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers. Int J Pharm. 2014;477:519\u201326. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.10.067.","journal-title":"Int J Pharm"},{"key":"3354_CR126","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijpharm.2010.09.007","volume":"401","author":"Y Agrawal","year":"2010","unstructured":"Agrawal Y, Petkar KC, Sawant KK. Development, evaluation and clinical studies of acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm. 2010;401:93\u2013102. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.09.007.","journal-title":"Int J Pharm"},{"key":"3354_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101568","volume":"56","author":"A Sharma","year":"2020","unstructured":"Sharma A, Upadhyay DK, Sarma GS, Kaur N, Gupta GD, Narang RK, et al. Squalene integrated NLC based gel of tamoxifen citrate for efficient treatment of psoriasis: a preclinical investigation. J Drug Deliv Sci Technol. 2020;56:101568. https:\/\/doi.org\/10.1016\/j.jddst.2020.101568.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3354_CR128","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2174\/2211738506666180523112513","volume":"6","author":"N Kaur","year":"2018","unstructured":"Kaur N, Sharma K, Bedi N. Topical nanostructured lipid carrier based hydrogel of mometasone furoate for the treatment of psoriasis. Pharm Nanotechnol. 2018;6:133\u201343. https:\/\/doi.org\/10.2174\/2211738506666180523112513.","journal-title":"Pharm Nanotechnol"},{"key":"3354_CR129","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s13346-020-00723-6","volume":"10","author":"JSR Viegas","year":"2020","unstructured":"Viegas JSR, Pra\u00e7a FG, Caron AL, Suzuki I, Silvestrini AVP, Medina WSG, et al. Nanostructured lipid carrier co-delivering tacrolimus and TNF-\u03b1 siRNA as an innovate approach to psoriasis. Drug Deliv Transl Res. 2020;10:646\u201360. https:\/\/doi.org\/10.1007\/s13346-020-00723-6.","journal-title":"Drug Deliv Transl Res"},{"key":"3354_CR130","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/jphp.12543","volume":"68","author":"LAD Silva","year":"2016","unstructured":"Silva LAD, Andrade LM, de S\u00e1 FAP, Marreto RN, Lima EM, Gratieri T, et al. Clobetasol-loaded nanostructured lipid carriers for epidermal targeting. J Pharm Pharmacol. 2016;68:742\u201350. https:\/\/doi.org\/10.1111\/jphp.12543.","journal-title":"J Pharm Pharmacol"},{"key":"3354_CR131","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4103\/pm.pm_260_19","volume":"16","author":"P Iriventi","year":"2020","unstructured":"Iriventi P, Gupta V. Topical delivery of curcumin and caffeine mixture-loaded nanostructured lipid carriers for effective treatment of psoriasis. Pharmacogn Mag. 2020;16:206\u201317.","journal-title":"Pharmacogn Mag"},{"key":"3354_CR132","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1080\/03639045.2019.1576722","volume":"45","author":"P Sathe","year":"2019","unstructured":"Sathe P, Saka R, Kommineni N, Raza K, Khan W. Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model. Drug Dev Ind Pharm. 2019;45:826\u201338. https:\/\/doi.org\/10.1080\/03639045.2019.1576722.","journal-title":"Drug Dev Ind Pharm"},{"key":"3354_CR133","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.msec.2017.05.036","volume":"79","author":"V Prasad","year":"2017","unstructured":"Prasad V, Chaurasia S. Performance evaluation of non-ionic surfactant based tazarotene encapsulated proniosomal gel for the treatment of psoriasis. Mater Sci Eng C Mater Biol Appl. 2017;79:168\u201376. https:\/\/doi.org\/10.1016\/j.msec.2017.05.036.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"3354_CR134","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.msec.2016.07.043","volume":"69","author":"SRM Moghddam","year":"2016","unstructured":"Moghddam SRM, Ahad A, Aqil M, Imam SS, Sultana Y. Formulation and optimization of niosomes for topical diacerein delivery using 3-factor, 3-level Box-Behnken design for the management of psoriasis. Mater Sci Eng C Mater Biol Appl. 2016;69:789\u201397. https:\/\/doi.org\/10.1016\/j.msec.2016.07.043.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"3354_CR135","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4103\/0378-6323.32709","volume":"73","author":"PK Lakshmi","year":"2007","unstructured":"Lakshmi PK, Devi GS, Bhaskaran S, Sacchidanand S. Niosomal methotrexate gel in the treatment of localized psoriasis: phase i and phase II studies. Indian J Dermatol Venereol Leprol. 2007;73:157\u201361. https:\/\/doi.org\/10.4103\/0378-6323.32709.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"3354_CR136","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.2147\/IJN.S156412","volume":"13","author":"II Abu Hashim","year":"2018","unstructured":"Abu Hashim II, Abo El-Magd NF, El-Sheakh AR, Hamed MF, Abd El-Gawad AE-GH. Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo-in vivo evaluation study. Int J Nanomedicine. 2018;13:1059\u201379. https:\/\/doi.org\/10.2147\/IJN.S156412.","journal-title":"Int J Nanomedicine"},{"key":"3354_CR137","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ijpharm.2015.03.020","volume":"485","author":"AA Abdelbary","year":"2015","unstructured":"Abdelbary AA, AbouGhaly MHH. Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study. Int J Pharm. 2015;485:235\u201343. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.03.020.","journal-title":"Int J Pharm"},{"key":"3354_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120826","volume":"605","author":"X Yang","year":"2021","unstructured":"Yang X, Tang Y, Wang M, Wang Y, Wang W, Pang M, et al. Co-delivery of methotrexate and nicotinamide by cerosomes for topical psoriasis treatment with enhanced efficacy. Int J Pharm. 2021;605:120826. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120826.","journal-title":"Int J Pharm"},{"key":"3354_CR139","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jare.2016.03.003","volume":"7","author":"SA Iizhar","year":"2016","unstructured":"Iizhar SA, Syed IA, Satar R, Ansari SA. In vitro assessment of pharmaceutical potential of ethosomes entrapped with terbinafine hydrochloride. J Adv Res. 2016;7:453\u201361. https:\/\/doi.org\/10.1016\/j.jare.2016.03.003.","journal-title":"J Adv Res"},{"key":"3354_CR140","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2174\/2211738507666190906123643","volume":"7","author":"A Chandra","year":"2019","unstructured":"Chandra A, Aggarwal G, Manchanda S, Narula A. Development of topical gel of methotrexate incorporated ethosomes and salicylic acid for the treatment of psoriasis. Pharm Nanotechnol. 2019;7:362\u201374. https:\/\/doi.org\/10.2174\/2211738507666190906123643.","journal-title":"Pharm Nanotechnol"},{"key":"3354_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.102010","volume":"60","author":"N Kaur","year":"2020","unstructured":"Kaur N, Kaur M, Mahajan M, Jain SK. Development, characterization and evaluation of nanocarrier based formulations of antipsoriatic drug \u201cacitretin\u201d for skin targeting. J Drug Deliv Sci Technol. 2020;60:102010. https:\/\/doi.org\/10.1016\/j.jddst.2020.102010.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3354_CR142","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ijpharm.2014.06.001","volume":"471","author":"Y-T Zhang","year":"2014","unstructured":"Zhang Y-T, Shen L-N, Wu Z-H, Zhao J-H, Feng N-P. Comparison of ethosomes and liposomes for skin delivery of psoralen for psoriasis therapy. Int J Pharm. 2014;471:449\u201352. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.06.001.","journal-title":"Int J Pharm"},{"key":"3354_CR143","doi-asserted-by":"publisher","first-page":"48","DOI":"10.7150\/thno.29715","volume":"9","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Xia Q, Li Y, He Z, Li Z, Guo T, et al. CD44 assists the topical anti-psoriatic efficacy of curcumin-loaded hyaluronan-modified ethosomes: a new strategy for clustering drug in inflammatory skin. Theranostics. 2019;9:48\u201364. https:\/\/doi.org\/10.7150\/thno.29715.","journal-title":"Theranostics"},{"key":"3354_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120762","volume":"604","author":"T Guo","year":"2021","unstructured":"Guo T, Lu J, Fan Y, Zhang Y, Yin S, Sha X, et al. TPGS assists the percutaneous administration of curcumin and glycyrrhetinic acid coloaded functionalized ethosomes for the synergistic treatment of psoriasis. Int J Pharm. 2021;604:120762. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120762.","journal-title":"Int J Pharm"},{"key":"3354_CR145","doi-asserted-by":"publisher","unstructured":"Gizaway SE, Fadel M, Mourad B, Elnaby FE-ZA. Betamethasone dipropionate gel for treatment of localized plaque psoriasis. Int J Pharm Pharm Sci. 2017 [cited 2025 Sept 8];9. \nhttps:\/\/doi.org\/10.22159\/ijpps.2017v9i8.18571.","DOI":"10.22159\/ijpps.2017v9i8.18571"},{"key":"3354_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102758","volume":"65","author":"RP Dhavale","year":"2021","unstructured":"Dhavale RP, Nadaf SJ, Bhatia MS. Quantitative structure property relationship assisted development of Fluocinolone acetonide loaded transfersomes for targeted delivery. J Drug Deliv Sci Technol. 2021;65:102758. https:\/\/doi.org\/10.1016\/j.jddst.2021.102758.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3354_CR147","doi-asserted-by":"publisher","first-page":"9","DOI":"10.30880\/jsmpm.2022.02.02.002","volume":"2","author":"K Motwani","year":"2022","unstructured":"Motwani K, Gupta V. Nano-transfersomes of vitamin-E and aloe-vera for the management of psoriasis: nano- transfersomes for the management of psoriasis. Journal of Sustainable Materials Processing and Management. 2022;2:9\u201318.","journal-title":"Journal of Sustainable Materials Processing and Management"},{"key":"3354_CR148","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.actbio.2024.06.006","volume":"184","author":"Y Xu","year":"2024","unstructured":"Xu Y, Gan Y, Qi F, Lu X, Zhang X, Zhang J, et al. Innate lymphoid cell-based immunomodulatory hydrogel microspheres containing Cutibacterium acnes extracellular vesicles for the treatment of psoriasis. Acta Biomater. 2024;184:296\u2013312. https:\/\/doi.org\/10.1016\/j.actbio.2024.06.006.","journal-title":"Acta Biomater"},{"key":"3354_CR149","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.dit.2013.02.001","volume":"5","author":"MdS Alam","year":"2013","unstructured":"Alam MdS, Ali MdS, Alam N, Siddiqui MR, Shamim Md, Safhi MM. In vivo study of clobetasol propionate loaded nanoemulsion for topical application in psoriasis and atopic dermatitis. Drug Invent Today. 2013;5:8\u201312. https:\/\/doi.org\/10.1016\/j.dit.2013.02.001.","journal-title":"Drug Invent Today"},{"key":"3354_CR150","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.nano.2017.02.009","volume":"13","author":"A Kaur","year":"2017","unstructured":"Kaur A, Katiyar SS, Kushwah V, Jain S. Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis. Nanomedicine. 2017;13:1473\u201382. https:\/\/doi.org\/10.1016\/j.nano.2017.02.009.","journal-title":"Nanomedicine"},{"key":"3354_CR151","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.2147\/IJN.S125302","volume":"12","author":"SH Musa","year":"2017","unstructured":"Musa SH, Basri M, Masoumi HRF, Shamsudin N, Salim N. Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action. IJN Dove Press. 2017;12:2427\u201341. https:\/\/doi.org\/10.2147\/IJN.S125302.","journal-title":"IJN. Dove Press"},{"key":"3354_CR152","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jddst.2018.12.020","volume":"49","author":"P Rajitha","year":"2019","unstructured":"Rajitha P, Shammika P, Aiswarya S, Gopikrishnan A, Jayakumar R, Sabitha M. Chaulmoogra oil based methotrexate loaded topical nanoemulsion for the treatment of psoriasis. J Drug Deliv Sci Technol. 2019;49:463\u201376. https:\/\/doi.org\/10.1016\/j.jddst.2018.12.020.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3354_CR153","doi-asserted-by":"publisher","DOI":"10.1186\/1477-3155-9-44","volume":"9","author":"DS Bernardi","year":"2011","unstructured":"Bernardi DS, Pereira TA, Maciel NR, Bortoloto J, Viera GS, Oliveira GC, et al. Formation and stability of oil-in-water nanoemulsions containing rice bran oil: in vitro and in vivo assessments. J Nanobiotechnology. 2011;9:44. https:\/\/doi.org\/10.1186\/1477-3155-9-44.","journal-title":"J Nanobiotechnology"},{"key":"3354_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101847","volume":"59","author":"MS Algahtani","year":"2020","unstructured":"Algahtani MS, Ahmad MZ, Ahmad J. Nanoemulsion loaded polymeric hydrogel for topical delivery of curcumin in psoriasis. J Drug Deliv Sci Technol. 2020;59:101847. https:\/\/doi.org\/10.1016\/j.jddst.2020.101847.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3354_CR155","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3109\/03639045.2015.1062512","volume":"42","author":"M Nasr","year":"2016","unstructured":"Nasr M, Abdel-Hamid S. Optimizing the dermal accumulation of a tazarotene microemulsion using skin deposition modeling. Drug Dev Ind Pharm. 2016;42:636\u201343. https:\/\/doi.org\/10.3109\/03639045.2015.1062512.","journal-title":"Drug Dev Ind Pharm"},{"key":"3354_CR156","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21020231","volume":"21","author":"GAdeS Cintra","year":"2016","unstructured":"Cintra GAdeS, Pinto LA, Calixto GMF, Soares CP, Von Zuben EdeS, Scarpa MV, et al. Bioadhesive surfactant systems for methotrexate skin delivery. Molecules. 2016;21:231. https:\/\/doi.org\/10.3390\/molecules21020231.","journal-title":"Molecules"},{"key":"3354_CR157","unstructured":"Admin. Formulation and evaluation of anthralin microemulsion gel using karanj oil. Int J Pharm Sci Res. 2014 [cited 2025 Sept 8]. https:\/\/ijpsr.com\/bft-article\/formulation-and-evaluation-of-anthralin-microemulsion-gel-using-karanj-oil\/. Accessed 8 Sept 2025."},{"key":"3354_CR158","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3109\/1061186X.2013.771778","volume":"21","author":"U Agrawal","year":"2013","unstructured":"Agrawal U, Mehra NK, Gupta U, Jain NK. Hyperbranched dendritic nano-carriers for topical delivery of dithranol. J Drug Target. 2013;21:497\u2013506. https:\/\/doi.org\/10.3109\/1061186X.2013.771778.","journal-title":"J Drug Target"},{"key":"3354_CR159","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ijpharm.2012.01.041","volume":"426","author":"K Borowska","year":"2012","unstructured":"Borowska K, Wo\u0142owiec S, Rubaj A, G\u0142owniak K, Sieniawska E, Radej S. Effect of polyamidoamine dendrimer G3 and G4 on skin permeation of 8-methoxypsoralene - in vivo study. Int J Pharm. 2012;426:280\u20133. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.01.041.","journal-title":"Int J Pharm"},{"key":"3354_CR160","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ijpharm.2018.08.024","volume":"550","author":"P Pandi","year":"2018","unstructured":"Pandi P, Jain A, Kommineni N, Ionov M, Bryszewska M, Khan W. Dendrimer as a new potential carrier for topical delivery of siRNA: a comparative study of dendriplex vs. lipoplex for delivery of TNF-\u03b1 siRNA. Int J Pharm. 2018;550:240\u201350. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.08.024.","journal-title":"Int J Pharm"},{"key":"3354_CR161","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1080\/10717544.2018.1436098","volume":"25","author":"WH Abd-Elsalam","year":"2018","unstructured":"Abd-Elsalam WH, El-Zahaby SA, Al-Mahallawi AM. Formulation and in vivo assessment of terconazole-loaded polymeric mixed micelles enriched with Cremophor EL as dual functioning mediator for augmenting physical stability and skin delivery. Drug Deliv. 2018;25:484\u201392. https:\/\/doi.org\/10.1080\/10717544.2018.1436098.","journal-title":"Drug Deliv"},{"key":"3354_CR162","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1021\/mp400639e","volume":"11","author":"M Lapteva","year":"2014","unstructured":"Lapteva M, Mondon K, M\u00f6ller M, Gurny R, Kalia YN, American Chemical Society. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis. Mol Pharm. 2014;11:2989\u20133001. https:\/\/doi.org\/10.1021\/mp400639e.","journal-title":"Mol Pharm"},{"key":"3354_CR163","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2174\/1567201817666200722141807","volume":"17","author":"F Chavoshy","year":"2020","unstructured":"Chavoshy F, Zadeh BSM, Tamaddon AM, Anbardar MH. Delivery and anti-psoriatic effect of silibinin-loaded polymeric micelles: an experimental study in the psoriatic skin model. Curr Drug Deliv. 2020;17:787\u201398. https:\/\/doi.org\/10.2174\/1567201817666200722141807.","journal-title":"Curr Drug Deliv"},{"key":"3354_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120736","volume":"604","author":"J Quartier","year":"2021","unstructured":"Quartier J, Lapteva M, Boulaguiem Y, Guerrier S, Kalia YN. Polymeric micelle formulations for the cutaneous delivery of sirolimus: a new approach for the treatment of facial angiofibromas in tuberous sclerosis complex. Int J Pharm. 2021;604:120736. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120736.","journal-title":"Int J Pharm"},{"key":"3354_CR165","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jsps.2016.06.009","volume":"25","author":"R Ali","year":"2017","unstructured":"Ali R, Farah A, Binkhathlan Z. Development and characterization of methoxy poly(ethylene oxide)-block-poly(\u03b5-caprolactone) (PEO-b-PCL) micelles as vehicles for the solubilization and delivery of tacrolimus. Saudi Pharm J. 2017;25:258\u201365. https:\/\/doi.org\/10.1016\/j.jsps.2016.06.009.","journal-title":"Saudi Pharm J"},{"key":"3354_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101901","volume":"59","author":"B Khurana","year":"2020","unstructured":"Khurana B, Arora D, Narang RK. QbD based exploration of resveratrol loaded polymeric micelles based carbomer gel for topical treatment of plaque psoriasis: in vitro, ex vivo and in vivo studies. J Drug Deliv Sci Technol. 2020;59:101901. https:\/\/doi.org\/10.1016\/j.jddst.2020.101901.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3354_CR167","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jconrel.2014.09.021","volume":"196","author":"M Lapteva","year":"2014","unstructured":"Lapteva M, Santer V, Mondon K, Patmanidis I, Chiriano G, Scapozza L, et al. Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter-cluster regions as molecular transport pathways. J Control Release. 2014;196:9\u201318. https:\/\/doi.org\/10.1016\/j.jconrel.2014.09.021.","journal-title":"J Control Release"},{"key":"3354_CR168","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1021\/acsabm.0c00342","volume":"3","author":"D Guo","year":"2020","unstructured":"Guo D, Shi C, Wang L, Ji X, Zhang S, Luo J. Rationally designed micellar nanocarriers for the delivery of hydrophilic Methotrexate in psoriasis treatment. ACS Appl Bio Mater. 2020;3:4832\u201346. https:\/\/doi.org\/10.1021\/acsabm.0c00342.","journal-title":"ACS Appl Bio Mater"},{"key":"3354_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124026","volume":"655","author":"A Sontakke","year":"2024","unstructured":"Sontakke A, Dighe S, Sharma R, Yadav V, Jain S. Harnessing the potential of fatty acid-surfactant-based micellar gel for enhanced topical delivery of Apremilast in psoriasis treatment. Int J Pharm. 2024;655:124026. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124026.","journal-title":"Int J Pharm"},{"key":"3354_CR170","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jaad.2003.09.018","volume":"50","author":"A Ehrlich","year":"2004","unstructured":"Ehrlich A, Booher S, Becerra Y, Borris DL, Figg WD, Turner ML, et al. Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. J Am Acad Dermatol. 2004;50:533\u201340. https:\/\/doi.org\/10.1016\/j.jaad.2003.09.018.","journal-title":"J Am Acad Dermatol"},{"key":"3354_CR171","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.clim.2016.03.009","volume":"165","author":"T Fan","year":"2016","unstructured":"Fan T, Wang S, Yu L, Yi H, Liu R, Geng W, et al. Treating psoriasis by targeting its susceptibility gene Rel. Clin Immunol. 2016;165:47\u201354. https:\/\/doi.org\/10.1016\/j.clim.2016.03.009.","journal-title":"Clin Immunol"},{"key":"3354_CR172","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3109\/03639041003598960","volume":"36","author":"ML Marchiori","year":"2010","unstructured":"Marchiori ML, Lubini G, Dalla Nora G, Friedrich RB, Fontana MC, Ourique AF, et al. Hydrogel containing dexamethasone-loaded nanocapsules for cutaneous administration: preparation, characterization, and in vitro drug release study. Drug Dev Ind Pharm. 2010;36:962\u201371. https:\/\/doi.org\/10.3109\/03639041003598960.","journal-title":"Drug Dev Ind Pharm"},{"key":"3354_CR173","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.msec.2014.10.011","volume":"46","author":"AL Savian","year":"2015","unstructured":"Savian AL, Rodrigues D, Weber J, Ribeiro RF, Motta MH, Schaffazick SR, et al. Dithranol-loaded lipid-core nanocapsules improve the photostability and reduce the in vitro irritation potential of this drug. Mater Sci Eng C Mater Biol Appl. 2015;46:69\u201376. https:\/\/doi.org\/10.1016\/j.msec.2014.10.011.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"3354_CR174","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000354921","volume":"27","author":"A Melero","year":"2014","unstructured":"Melero A, Ferreira Ourique A, Stanis\u00e7uaski Guterres S, Raffin Pohlmann A, Lehr C-M, Ruver Beck RC, et al. Nanoencapsulation in lipid-core nanocapsules controls mometasone furoate skin permeability rate and its penetration to the deeper skin layers. Skin Pharmacol Physiol. 2014;27:217. https:\/\/doi.org\/10.1159\/000354921.","journal-title":"Skin Pharmacol Physiol"},{"key":"3354_CR175","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1021\/bm050212u","volume":"6","author":"L Sheihet","year":"2005","unstructured":"Sheihet L, Dubin RA, Devore D, Kohn J. Hydrophobic drug delivery by self-assembling triblock copolymer-derived nanospheres. Biomacromolecules. 2005;6:2726\u201331. https:\/\/doi.org\/10.1021\/bm050212u.","journal-title":"Biomacromolecules"},{"key":"3354_CR176","doi-asserted-by":"publisher","unstructured":"Priyanka NVS, Neeraja P, Mangilal T, Kumar MR. Formulation and evaluation of gel loaded with microspheres of apremilast for transdermal delivery system. Asian J Pharm Clin Res. 2019;411\u20137. \nhttps:\/\/doi.org\/10.22159\/ajpcr.2019.v12i2.29374.","DOI":"10.22159\/ajpcr.2019.v12i2.29374"},{"key":"3354_CR177","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.107000","volume":"205","author":"N Jin","year":"2025","unstructured":"Jin N, Huang L, Chen X, Liu Z, Chen R, Gao M, et al. Psoriatic skin-sensitive degradable mesoporous zinc phosphate microsphere as a photosensitizer in photodynamic therapy for anti-psoriasis. Eur J Pharm Sci. 2025;205:107000. https:\/\/doi.org\/10.1016\/j.ejps.2024.107000.","journal-title":"Eur J Pharm Sci"},{"key":"3354_CR178","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jconrel.2013.04.021","volume":"170","author":"PR Desai","year":"2013","unstructured":"Desai PR, Marepally S, Patel AR, Voshavar C, Chaudhuri A, Singh M. Topical delivery of anti-TNF\u03b1 siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J Control Release. 2013;170:51\u201363. https:\/\/doi.org\/10.1016\/j.jconrel.2013.04.021.","journal-title":"J Control Release"},{"key":"3354_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.116562","volume":"234","author":"SA Hazari","year":"2023","unstructured":"Hazari SA, Sheikh A, Abourehab MAS, Tulbah AS, Kesharwani P. Self-assembled gallic acid loaded lecithin-chitosan hybrid nanostructured gel as a potential tool against imiquimod-induced psoriasis. Environ Res. 2023;234:116562. https:\/\/doi.org\/10.1016\/j.envres.2023.116562.","journal-title":"Environ Res"},{"key":"3354_CR180","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-021-02116-5","volume":"22","author":"SS Pukale","year":"2021","unstructured":"Pukale SS, Mittal A, Chitkara D. Topical application of vitamin D3-loaded hybrid nanosystem to offset imiquimod-induced psoriasis. AAPS PharmSciTech. 2021;22:238. https:\/\/doi.org\/10.1208\/s12249-021-02116-5.","journal-title":"AAPS PharmSciTech"},{"key":"3354_CR181","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.actbio.2020.08.020","volume":"115","author":"SS Pukale","year":"2020","unstructured":"Pukale SS, Sharma S, Dalela M, Singh AK, Mohanty S, Mittal A, et al. Multi-component clobetasol-loaded monolithic lipid-polymer hybrid nanoparticles ameliorate imiquimod-induced psoriasis-like skin inflammation in Swiss albino mice. Acta Biomater. 2020;115:393\u2013409. https:\/\/doi.org\/10.1016\/j.actbio.2020.08.020.","journal-title":"Acta Biomater"},{"key":"3354_CR182","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jconrel.2021.08.039","volume":"338","author":"IL Suzuki","year":"2021","unstructured":"Suzuki IL, de Araujo MM, Bagnato VS, Bentley MVLB. TNF\u03b1 siRNA delivery by nanoparticles and photochemical internalization for psoriasis topical therapy. J Control Release. 2021;338:316\u201329. https:\/\/doi.org\/10.1016\/j.jconrel.2021.08.039.","journal-title":"J Control Release"},{"key":"3354_CR183","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121114","volume":"608","author":"SA Fereig","year":"2021","unstructured":"Fereig SA, El-Zaafarany GM, Arafa MG, Abdel-Mottaleb MMA. Self-assembled tacrolimus-loaded lecithin-chitosan hybrid nanoparticles for in vivo management of psoriasis. Int J Pharm. 2021;608:121114. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.121114.","journal-title":"Int J Pharm"},{"key":"3354_CR184","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.colsurfb.2016.01.021","volume":"141","author":"H Bessar","year":"2016","unstructured":"Bessar H, Venditti I, Benassi L, Vaschieri C, Azzoni P, Pellacani G, et al. Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. Colloids Surf B Biointerfaces. 2016;141:141\u20137. https:\/\/doi.org\/10.1016\/j.colsurfb.2016.01.021.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3354_CR185","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/exd.13707","volume":"27","author":"D Crisan","year":"2018","unstructured":"Crisan D, Scharffetter-Kochanek K, Crisan M, Schatz S, Hainzl A, Olenic L, et al. Topical silver and gold nanoparticles complexed with Cornus mas suppress inflammation in human psoriasis plaques by inhibiting NF-\u03baB activity. Exp Dermatol. 2018;27:1166\u20139. https:\/\/doi.org\/10.1111\/exd.13707.","journal-title":"Exp Dermatol"},{"key":"3354_CR186","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.msec.2018.10.061","volume":"95","author":"N Raghuwanshi","year":"2019","unstructured":"Raghuwanshi N, Yadav TC, Srivastava AK, Raj U, Varadwaj P, Pruthi V. Structure-based drug designing and identification of Woodfordia fruticosa inhibitors targeted against heat shock protein (HSP70-1) as suppressor for Imiquimod-induced psoriasis like skin inflammation in mice model. Mater Sci Eng C Mater Biol Appl. 2019;95:57\u201371. https:\/\/doi.org\/10.1016\/j.msec.2018.10.061.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"3354_CR187","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.nano.2019.01.006","volume":"17","author":"I Fratoddi","year":"2019","unstructured":"Fratoddi I, Benassi L, Botti E, Vaschieri C, Venditti I, Bessar H, et al. Effects of topical methotrexate loaded gold nanoparticle in cutaneous inflammatory mouse model. Nanomedicine. 2019;17:276\u201386. https:\/\/doi.org\/10.1016\/j.nano.2019.01.006.","journal-title":"Nanomedicine"},{"key":"3354_CR188","doi-asserted-by":"publisher","unstructured":"Han R, Ho LWC, Bai Q, Chan CKW, Lee LKC, Choi PC-L, et al. Alkyl-terminated gold nanoparticles as a self-therapeutic treatment for psoriasis. Nano Lett. 2021;21:8723\u201333. \nhttps:\/\/doi.org\/10.1021\/acs.nanolett.1c02899.","DOI":"10.1021\/acs.nanolett.1c02899"},{"key":"3354_CR189","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.colsurfb.2014.08.018","volume":"122","author":"L David","year":"2014","unstructured":"David L, Moldovan B, Vulcu A, Olenic L, Perde-Schrepler M, Fischer-Fodor E, et al. Green synthesis, characterization and anti-inflammatory activity of silver nanoparticles using European black elderberry fruits extract. Colloids Surf B Biointerfaces. 2014;122:767\u201377. https:\/\/doi.org\/10.1016\/j.colsurfb.2014.08.018.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3354_CR190","doi-asserted-by":"publisher","first-page":"8537","DOI":"10.2147\/IJN.S174530","volume":"13","author":"PBE Kedi","year":"2018","unstructured":"Kedi PBE, Meva FE, Kotsedi L, Nguemfo EL, Zangueu CB, Ntoumba AA, et al. Eco-friendly synthesis, characterization, in vitro and in vivo anti-inflammatory activity of silver nanoparticle-mediated Selaginella myosurus aqueous extract. Int J Nanomedicine. 2018;13:8537\u201348. https:\/\/doi.org\/10.2147\/IJN.S174530.","journal-title":"Int J Nanomedicine"},{"key":"3354_CR191","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.126234","volume":"685","author":"J Guo","year":"2025","unstructured":"Guo J, Zhang L, Li Z, Zhang Y, Yang N, Tang H, et al. A transdermal drug delivery system based on estradiol liposomes enhances the alleviation of psoriatic skin inflammation. Int J Pharm. 2025;685:126234. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.126234.","journal-title":"Int J Pharm"},{"key":"3354_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2024.114457","volume":"247","author":"P Zhang","year":"2025","unstructured":"Zhang P, Tang J, Cheng L, Xue Y, Yang J, Sun Z, et al. Hyaluronic acid modified liposomes with enhanced transdermal delivery of methotrexate for psoriasis treatment. Colloids Surf B Biointerfaces. 2025;247:114457. https:\/\/doi.org\/10.1016\/j.colsurfb.2024.114457.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3354_CR193","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115823","volume":"168","author":"P Rahmanian-Devin","year":"2023","unstructured":"Rahmanian-Devin P, Askari VR, Sanei-Far Z, Baradaran Rahimi V, Kamali H, Jaafari MR, et al. Preparation and characterization of solid lipid nanoparticles encapsulated noscapine and evaluation of its protective effects against imiquimod-induced psoriasis-like skin lesions. Biomed Pharmacother. 2023;168:115823. https:\/\/doi.org\/10.1016\/j.biopha.2023.115823.","journal-title":"Biomed Pharmacother"},{"key":"3354_CR194","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jsps.2023.04.007","volume":"31","author":"D Maiti","year":"2023","unstructured":"Maiti D, Naseeruddin Inamdar M, Almuqbil M, Suresh S, Mohammed Basheeruddin Asdaq S, Alshehri S, et al. Evaluation of solid-lipid nanoparticles formulation of methotrexate for anti-psoriatic activity. Saudi Pharm J. 2023;31:834\u201344. https:\/\/doi.org\/10.1016\/j.jsps.2023.04.007.","journal-title":"Saudi Pharm J"},{"key":"3354_CR195","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17040478","author":"A Rani","year":"2025","unstructured":"Rani A, Kaur R, Aldahish A, Vasudevan R, Balaji P, Dora CP, et al. Nanostructured lipid carriers (NLC)-based topical formulation of hesperidin for effective treatment of psoriasis. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/pharmaceutics17040478.","journal-title":"Pharmaceutics"},{"key":"3354_CR196","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124172","volume":"660","author":"P Kakade","year":"2024","unstructured":"Kakade P, Patravale V, Patil A, Disouza J. Formulation development of nanostructured lipid carrier-based nanogels encapsulating tacrolimus for sustained therapy of psoriasis. Int J Pharm. 2024;660:124172. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124172.","journal-title":"Int J Pharm"},{"key":"3354_CR197","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106612","volume":"191","author":"S Hatem","year":"2023","unstructured":"Hatem S, El-Kayal M. Novel anti-psoriatic nanostructured lipid carriers for the cutaneous delivery of luteolin: a comprehensive in-vitro and in-vivo evaluation. Eur J Pharm Sci. 2023;191:106612. https:\/\/doi.org\/10.1016\/j.ejps.2023.106612.","journal-title":"Eur J Pharm Sci"},{"key":"3354_CR198","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1517\/17425247.2012.686490","volume":"9","author":"M Gupta","year":"2012","unstructured":"Gupta M, Agrawal U, Vyas SP. Nanocarrier-based topical drug delivery for the treatment of skin diseases. Expert Opin Drug Deliv. 2012;9:783\u2013804. https:\/\/doi.org\/10.1517\/17425247.2012.686490.","journal-title":"Expert Opin Drug Deliv"},{"key":"3354_CR199","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-72951-6","volume":"14","author":"Y Mehmood","year":"2024","unstructured":"Mehmood Y, Shahid H, Ahmed S, Khursheed A, Jamshaid T, Jamshaid M, et al. Synthesis of vitamin D3 loaded ethosomes gel to cure chronic immune-mediated inflammatory skin disease: physical characterization, in vitro and ex vivo studies. Sci Rep. 2024;14:23866. https:\/\/doi.org\/10.1038\/s41598-024-72951-6.","journal-title":"Sci Rep"},{"key":"3354_CR200","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4103\/2231-4040.85524","volume":"2","author":"R Rajan","year":"2011","unstructured":"Rajan R, Jose S, Mukund VPB, Vasudevan DT. Transferosomes - a vesicular transdermal delivery system for enhanced drug permeation. J Adv Pharm Technol Res. 2011;2:138\u201343. https:\/\/doi.org\/10.4103\/2231-4040.85524.","journal-title":"J Adv Pharm Technol Res"},{"key":"3354_CR201","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13122129","volume":"13","author":"E Touitou","year":"2021","unstructured":"Touitou E, Natsheh H. Topical administration of drugs incorporated in carriers containing phospholipid soft vesicles for the treatment of skin medical conditions. Pharmaceutics. 2021;13:2129. https:\/\/doi.org\/10.3390\/pharmaceutics13122129.","journal-title":"Pharmaceutics"},{"key":"3354_CR202","doi-asserted-by":"publisher","DOI":"10.3390\/ph18040594","author":"S Shinde","year":"2025","unstructured":"Shinde S, Singh AK, Chidrawar VR, Rajput A, Singh S, Shinde S. Enhanced topical delivery of methotrexate via transferosome-loaded microneedle array patch: formulation, optimization, and in vitro\u2013in vivo assessment. Pharmaceuticals. 2025. https:\/\/doi.org\/10.3390\/ph18040594.","journal-title":"Pharmaceuticals"},{"key":"3354_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2025.106731","volume":"106","author":"S Singh","year":"2025","unstructured":"Singh S, Awasthi R. Topical transferosomal gel of berberine HCl and diacerein reduced TNF-\u03b1 and IL-17A levels and reduced epidermal thickness in imiquimod-induced psoriatic BALB\/c mice. J Drug Deliv Sci Technol. 2025;106:106731. https:\/\/doi.org\/10.1016\/j.jddst.2025.106731.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3354_CR204","doi-asserted-by":"publisher","DOI":"10.1039\/d4md00781f","author":"K Chen","year":"2025","unstructured":"Chen K, Yang H, Xu G, Hu Y, Tian X, Qin S, et al. Enhanced skin penetration of curcumin by a nanoemulsion-embedded oligopeptide hydrogel for psoriasis topical therapy. RSC Med Chem. 2025. https:\/\/doi.org\/10.1039\/d4md00781f.","journal-title":"RSC Med Chem"},{"key":"3354_CR205","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.48047\/cbt7t656","volume":"54","author":"VK Singh","year":"2025","unstructured":"Singh VK, Patel HA. A unique strategies for psoriasis management: utilizing nanoemulsion based insitu-gel formulation for topical administration of mometasone furoate. Cuest Fisioter. 2025;54:3448\u201360. https:\/\/doi.org\/10.48047\/cbt7t656.","journal-title":"Cuest Fisioter"},{"key":"3354_CR206","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.nano.2017.06.009","volume":"13","author":"A Jain","year":"2017","unstructured":"Jain A, Pooladanda V, Bulbake U, Doppalapudi S, Rafeeqi TA, Godugu C, et al. Liposphere mediated topical delivery of thymoquinone in the treatment of psoriasis. Nanomedicine. 2017;13:2251\u201362. https:\/\/doi.org\/10.1016\/j.nano.2017.06.009.","journal-title":"Nanomedicine"},{"key":"3354_CR207","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05030-z","volume":"22","author":"YJ Park","year":"2024","unstructured":"Park YJ, Kim DC, Lee S-J, Kim HS, Pak JY, Kim J, et al. Keratinocyte-derived circulating microRNAs in extracellular vesicles: a novel biomarker of psoriasis severity and potential therapeutic target. J Transl Med. 2024;22:235. https:\/\/doi.org\/10.1186\/s12967-024-05030-z.","journal-title":"J Transl Med"},{"key":"3354_CR208","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-10886-2","volume":"15","author":"MS Kishta","year":"2025","unstructured":"Kishta MS, Abd-Rabou AA, Sarkissian GK, Elwakil AI, Elsabry DM, Zagzoug YM, et al. Exosome mediated delivery of Epigallocatechin 3 gallate as a novel approach to alleviate psoriasis symptoms through cytokine and apoptotic pathway modulation. Sci Rep Nature Publishing Group. 2025;15:30013. https:\/\/doi.org\/10.1038\/s41598-025-10886-2.","journal-title":"Sci Rep. Nature Publishing Group"},{"key":"3354_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122915","volume":"353","author":"MA Mohseni Meybodi","year":"2024","unstructured":"Mohseni Meybodi MA, Nilforoushzadeh MA, KhandanDezfully N, Mansouri P. The safety and efficacy of adipose tissue-derived exosomes in treating mild to moderate plaque psoriasis: a clinical study. Life Sci. 2024;353:122915. https:\/\/doi.org\/10.1016\/j.lfs.2024.122915.","journal-title":"Life Sci"},{"key":"3354_CR210","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadva.2021.100039","volume":"2","author":"F Strati","year":"2022","unstructured":"Strati F, Mukhina T, Neubert RHH, Opalka L, Hause G, Schmelzer CEH, et al. Cerosomes as skin repairing agent: mode of action studies with a model stratum corneum layer at liquid\/air and liquid\/solid interfaces. BBA Adv. 2022;2:100039. https:\/\/doi.org\/10.1016\/j.bbadva.2021.100039.","journal-title":"BBA Adv"},{"key":"3354_CR211","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1080\/17435889.2024.2405455","volume":"19","author":"S Thatikonda","year":"2024","unstructured":"Thatikonda S, Rasoju SP, Pooladanda V, Chilvery S, Khemchandani R, Samanthula G, et al. Niosomal gel improves dermal delivery of nimbolide: a promising approach for treatment of psoriasis. Nanomedicine (Lond). 2024;19:2521\u201336. https:\/\/doi.org\/10.1080\/17435889.2024.2405455.","journal-title":"Nanomedicine (Lond)"},{"key":"3354_CR212","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202400410","volume":"357","author":"AY Moussa","year":"2024","unstructured":"Moussa AY, Abbas H, Zewail M, Gaafar PME, Ibrahim N. Green preparation and evaluation of the anti-psoriatic activity of vesicular elastic nanocarriers of kojic acid from Aspergillus oryzae N12: repurposing of a dermo-cosmetic lead. Arch Pharm Weinheim. 2024;357:e2400410. https:\/\/doi.org\/10.1002\/ardp.202400410.","journal-title":"Arch Pharm Weinheim"},{"key":"3354_CR213","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1407782","volume":"15","author":"L Yao","year":"2024","unstructured":"Yao L, Tian F, Meng Q, Guo L, Ma Z, Hu T, et al. Reactive oxygen species-responsive supramolecular deucravacitinib self-assembly polymer micelles alleviate psoriatic skin inflammation by reducing mitochondrial oxidative stress. Front Immunol. 2024;15:1407782. https:\/\/doi.org\/10.3389\/fimmu.2024.1407782.","journal-title":"Front Immunol"},{"key":"3354_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118556","volume":"568","author":"E Elmowafy","year":"2019","unstructured":"Elmowafy E, El-Gogary RI, Ragai MH, Nasr M. Novel antipsoriatic fluidized spanlastic nanovesicles: in vitro physicochemical characterization, ex vivo cutaneous retention and exploratory clinical therapeutic efficacy. Int J Pharm. 2019;568:118556. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118556.","journal-title":"Int J Pharm"},{"key":"3354_CR215","doi-asserted-by":"publisher","first-page":"447","DOI":"10.13005\/bpj\/3099","volume":"18","author":"R Annisa","year":"2025","unstructured":"Annisa R. Spanlastic as a transdermal drug delivery system: a systematic review. Biomed Pharmacol J. 2025;18:447\u201357.","journal-title":"Biomed Pharmacol J"},{"key":"3354_CR216","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.3109\/21691401.2015.1037885","volume":"44","author":"T Garg","year":"2016","unstructured":"Garg T, Rath G, Goyal AK. Nanotechnological approaches for the effective management of psoriasis. Artif Cells Nanomed Biotechnol. 2016;44:1374\u201382. https:\/\/doi.org\/10.3109\/21691401.2015.1037885.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"3354_CR217","doi-asserted-by":"publisher","unstructured":"Jebbawi R, Oukhrib A, Clement E, Labie H, Cassel S, Fruchon S, et al. Increased anti-psoriatic effect of anti-inflammatory dendrimers using fluid catanionic vesicle-based topical formulations. Adv Healthc Mater. 2025;e03282. \nhttps:\/\/doi.org\/10.1002\/adhm.202503282.","DOI":"10.1002\/adhm.202503282"},{"key":"3354_CR218","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/ijn.s595","volume":"3","author":"J-UAH Junghanns","year":"2008","unstructured":"Junghanns J-UAH, M\u00fcller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3:295\u2013309. https:\/\/doi.org\/10.2147\/ijn.s595.","journal-title":"Int J Nanomedicine"},{"key":"3354_CR219","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s10787-023-01198-w","volume":"31","author":"Y Shahine","year":"2023","unstructured":"Shahine Y, El-Aal SAA, Reda AM, Sheta E, Atia NM, Abdallah OY, et al. Diosmin nanocrystal gel alleviates imiquimod-induced psoriasis in rats via modulating TLR7,8\/NF-\u03baB\/micro RNA-31, AKT\/mTOR\/P70S6K milieu, and Tregs\/Th17 balance. Inflammopharmacology. 2023;31:1341\u201359. https:\/\/doi.org\/10.1007\/s10787-023-01198-w.","journal-title":"Inflammopharmacology"},{"key":"3354_CR220","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.804415","volume":"9","author":"N Li","year":"2021","unstructured":"Li N, Qin Y, Dai D, Wang P, Shi M, Gao J, et al. Transdermal Delivery of Therapeutic Compounds With Nanotechnological Approaches in Psoriasis. Front Bioeng Biotechnol. 2021;9:804415. https:\/\/doi.org\/10.3389\/fbioe.2021.804415.","journal-title":"Front Bioeng Biotechnol"},{"key":"3354_CR221","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114634","volume":"162","author":"VK Rapalli","year":"2023","unstructured":"Rapalli VK, Tomar Y, Sharma S, Roy A, Singhvi G. Apremilast loaded lyotropic liquid crystalline nanoparticles embedded hydrogel for improved permeation and skin retention: an effective approach for psoriasis treatment. Biomed Pharmacother. 2023;162:114634. https:\/\/doi.org\/10.1016\/j.biopha.2023.114634.","journal-title":"Biomed Pharmacother"},{"key":"3354_CR222","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2217\/nnm-2018-0345","volume":"14","author":"MS Freag","year":"2019","unstructured":"Freag MS, Torky AS, Nasra MM, Abdelmonsif DA, Abdallah OY. Liquid crystalline nanoreservoir releasing a highly skin-penetrating berberine oleate complex for psoriasis management. Nanomedicine Lond. 2019;14:931\u201354. https:\/\/doi.org\/10.2217\/nnm-2018-0345.","journal-title":"Nanomedicine Lond"},{"key":"3354_CR223","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121873","volume":"622","author":"PK Parmar","year":"2022","unstructured":"Parmar PK, Sharma N, Wasil Kabeer S, Rohit A, Bansal AK. Nanocrystal-based gel of apremilast ameliorates imiquimod-induced psoriasis by suppressing inflammatory responses. Int J Pharm. 2022;622:121873. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121873.","journal-title":"Int J Pharm"},{"key":"3354_CR224","doi-asserted-by":"publisher","DOI":"10.1063\/5.0229803","volume":"12","author":"N Yang","year":"2024","unstructured":"Yang N, Huang Y, Dong C, Sun C, Xi P, Dai Y, et al. Nanozyme microspheres with structural color-coding labels for synergistic therapy of psoriasis. APL Mater. 2024;12:091102. https:\/\/doi.org\/10.1063\/5.0229803.","journal-title":"APL Mater"},{"key":"3354_CR225","doi-asserted-by":"publisher","DOI":"10.3390\/gels9110871","volume":"9","author":"Y Mehmood","year":"2023","unstructured":"Mehmood Y, Shahid H, ul Huq UI, Rafeeq H, Khalid HMB, Uddin MN, et al. Microsponge-based gel loaded with immunosuppressant as a simple and valuable strategy for psoriasis therapy: determination of pro-inflammatory response through cytokine IL-2 mRNA expression. Gels. 2023;9:871. https:\/\/doi.org\/10.3390\/gels9110871.","journal-title":"Gels"},{"key":"3354_CR226","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ajps.2019.05.004","volume":"15","author":"S Mahant","year":"2020","unstructured":"Mahant S, Kumar S, Nanda S, Rao R. Microsponges for dermatological applications: perspectives and challenges. Asian J Pharm Sci. 2020;15:273\u201391. https:\/\/doi.org\/10.1016\/j.ajps.2019.05.004.","journal-title":"Asian J Pharm Sci"},{"key":"3354_CR227","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.101347","volume":"55","author":"N Devi","year":"2020","unstructured":"Devi N, Kumar S, Prasad M, Rao R. Eudragit RS100 based microsponges for dermal delivery of clobetasol propionate in psoriasis management. J Drug Deliv Sci Technol. 2020;55:101347. https:\/\/doi.org\/10.1016\/j.jddst.2019.101347.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3354_CR228","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1166\/jbn.2009.1004","volume":"5","author":"E J\u00e4ger","year":"2009","unstructured":"J\u00e4ger E, Venturini CG, Poletto FS, Colom\u00e9 LM, Pohlmann JPU, Bernardi A, et al. Sustained release from lipid-core nanocapsules by varying the core viscosity and the particle surface area. J Biomed Nanotechnol. 2009;5:130\u201340. https:\/\/doi.org\/10.1166\/jbn.2009.1004.","journal-title":"J Biomed Nanotechnol"},{"key":"3354_CR229","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-024-02781-2","volume":"25","author":"EZ Dahmash","year":"2024","unstructured":"Dahmash EZ, Attiany LM, Ali D, Assaf SM, Alkrad J, Alyami H. Development and characterization of transdermal patches using novel thymoquinone-L-arginine-based polyamide nanocapsules for potential use in the management of psoriasis. AAPS PharmSciTech. 2024;25:69. https:\/\/doi.org\/10.1208\/s12249-024-02781-2.","journal-title":"AAPS PharmSciTech"},{"key":"3354_CR230","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ejpb.2006.11.009","volume":"65","author":"K Letchford","year":"2007","unstructured":"Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm. 2007;65:259\u201369. https:\/\/doi.org\/10.1016\/j.ejpb.2006.11.009.","journal-title":"Eur J Pharm Biopharm"},{"key":"3354_CR231","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0168-3659(99)00247-3","volume":"65","author":"GP Carino","year":"2000","unstructured":"Carino GP, Jacob JS, Mathiowitz E. Nanosphere based oral insulin delivery. J Control Release. 2000;65:261\u20139. https:\/\/doi.org\/10.1016\/S0168-3659(99)00247-3.","journal-title":"J Control Release"},{"key":"3354_CR232","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01849-0","volume":"22","author":"KR Gajbhiye","year":"2023","unstructured":"Gajbhiye KR, Salve R, Narwade M, Sheikh A, Kesharwani P, Gajbhiye V. Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics. Mol Cancer. 2023;22:160. https:\/\/doi.org\/10.1186\/s12943-023-01849-0.","journal-title":"Mol Cancer"},{"key":"3354_CR233","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1016\/j.apsb.2022.11.026","volume":"13","author":"W Zhang","year":"2023","unstructured":"Zhang W, Jiang Y, He Y, Boucetta H, Wu J, Chen Z, et al. Lipid carriers for mRNA delivery. Acta Pharm Sin B. 2023;13:4105\u201326. https:\/\/doi.org\/10.1016\/j.apsb.2022.11.026.","journal-title":"Acta Pharm Sin B"},{"key":"3354_CR234","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfa.2025.138853","volume":"730","author":"H Yan","year":"2026","unstructured":"Yan H, Kaliamoorthy S, Sivalingam L, Samikannu P, Tamilarasan R, Dharman G, et al. Enhanced dermal delivery of myrtenol via polymer-lipid nanoparticle hydrogel for psoriasis therapy. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2026;730:138853. https:\/\/doi.org\/10.1016\/j.colsurfa.2025.138853.","journal-title":"Colloids and Surfaces A: Physicochemical and Engineering Aspects"},{"key":"3354_CR235","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1017126","volume":"9","author":"M Zhang","year":"2022","unstructured":"Zhang M, Hong S, Sun X, Zhou Y, Luo Y, Liu L, et al. Exploration of and insights into advanced topical nanocarrier systems for the treatment of psoriasis. Front Med Lausanne. 2022;9:1017126. https:\/\/doi.org\/10.3389\/fmed.2022.1017126.","journal-title":"Front Med Lausanne"},{"key":"3354_CR236","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.biopha.2018.07.156","volume":"107","author":"M Pradhan","year":"2018","unstructured":"Pradhan M, Alexander A, Singh MR, Singh D, Saraf S, Saraf S. Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomed Pharmacother. 2018;107:447\u201363. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.156.","journal-title":"Biomed Pharmacother"},{"key":"3354_CR237","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02986-4","volume":"22","author":"J Li","year":"2024","unstructured":"Li J, Yuan Z, Shi S, Chen X, Yu S, Qi X, et al. Microneedle patches incorporating zinc-doped mesoporous silica nanoparticles loaded with betamethasone dipropionate for psoriasis treatment. J Nanobiotechnology. 2024;22:706. https:\/\/doi.org\/10.1186\/s12951-024-02986-4.","journal-title":"J Nanobiotechnology"},{"key":"3354_CR238","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.actbio.2015.05.036","volume":"24","author":"E Korkmaz","year":"2015","unstructured":"Korkmaz E, Friedrich EE, Ramadan MH, Erdos G, Mathers AR, Burak Ozdoganlar O, et al. Therapeutic intradermal delivery of tumor necrosis factor-alpha antibodies using tip-loaded dissolvable microneedle arrays. Acta Biomater. 2015;24:96\u2013105. https:\/\/doi.org\/10.1016\/j.actbio.2015.05.036.","journal-title":"Acta Biomater"},{"key":"3354_CR239","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejpb.2021.04.016","volume":"164","author":"L Liang","year":"2021","unstructured":"Liang L, Fei WM, Zhao ZQ, Hao YY, Zhang C, Cui Y, et al. Improved imiquimod-induced psoriasis like dermatitis using microneedles in mice. Eur J Pharm Biopharm. 2021;164:20\u20137. https:\/\/doi.org\/10.1016\/j.ejpb.2021.04.016.","journal-title":"Eur J Pharm Biopharm"},{"key":"3354_CR240","doi-asserted-by":"publisher","first-page":"43588","DOI":"10.1021\/acsami.9b15668","volume":"11","author":"H Du","year":"2019","unstructured":"Du H, Liu P, Zhu J, Lan J, Li Y, Zhang L, et al. Hyaluronic acid-based dissolving microneedle patch loaded with methotrexate for improved treatment of psoriasis. ACS Appl Mater Interfaces. 2019;11:43588\u201398. https:\/\/doi.org\/10.1021\/acsami.9b15668.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3354_CR241","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1067051","volume":"13","author":"C Wang","year":"2022","unstructured":"Wang C, Hao R, Peng B, Chang J, Chen S, Chen Y, et al. Dissolvable hyaluronic acid microneedles loaded with \u03b2-Elemene for the treatment of psoriasis. Front Pharmacol. 2022;13:1067051. https:\/\/doi.org\/10.3389\/fphar.2022.1067051.","journal-title":"Front Pharmacol"},{"key":"3354_CR242","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4103\/2230-973X.85963","volume":"1","author":"S Baboota","year":"2011","unstructured":"Baboota S, Alam MS, Sharma S, Sahni JK, Kumar A, Ali J. Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis. Int J Pharm Investig. 2011;1:139\u201347. https:\/\/doi.org\/10.4103\/2230-973X.85963.","journal-title":"Int J Pharm Investig"},{"key":"3354_CR243","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.colsurfb.2019.06.018","volume":"181","author":"D Lim\u00f3n","year":"2019","unstructured":"Lim\u00f3n D, Tall\u00f3 Dom\u00ednguez K, Gardu\u00f1o-Ram\u00edrez ML, Andrade B, Calpena AC, P\u00e9rez-Garc\u00eda L. Nanostructured supramolecular hydrogels: towards the topical treatment of Psoriasis and other skin diseases. Colloids Surf B Biointerfaces. 2019;181:657\u201370. https:\/\/doi.org\/10.1016\/j.colsurfb.2019.06.018.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3354_CR244","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bioactmat.2024.07.013","volume":"41","author":"Y Lai","year":"2024","unstructured":"Lai Y, Wu X, Jiang Z, Fang Y, Liu X, Hong D, et al. Topical treatment of tyrosine kinase 2 inhibitor through borneol-embedded hydrogel: evaluation for preventive, therapeutic, and recurrent management of psoriasis. Bioact Mater. 2024;41:83\u201395. https:\/\/doi.org\/10.1016\/j.bioactmat.2024.07.013.","journal-title":"Bioact Mater"},{"key":"3354_CR245","doi-asserted-by":"publisher","first-page":"17080","DOI":"10.1021\/acsami.3c17091","volume":"16","author":"B Lu","year":"2024","unstructured":"Lu B, Zhong Y, Zhang J, Zhang J, American Chemical Society. Curcumin-based ionic liquid hydrogel for topical transdermal delivery of curcumin to improve its therapeutic effect on the psoriasis mouse model. ACS Appl Mater Interfaces. 2024;16:17080\u201391. https:\/\/doi.org\/10.1021\/acsami.3c17091.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3354_CR246","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01368-y","volume":"20","author":"J Xu","year":"2022","unstructured":"Xu J, Chen H, Chu Z, Li Z, Chen B, Sun J, et al. A multifunctional composite hydrogel as an intrinsic and extrinsic coregulator for enhanced therapeutic efficacy for psoriasis. J Nanobiotechnology. 2022;20:155. https:\/\/doi.org\/10.1186\/s12951-022-01368-y.","journal-title":"J Nanobiotechnology"},{"key":"3354_CR247","doi-asserted-by":"publisher","unstructured":"Kumar S, Nair AB, Kadian V, Dalal P, Jangir BL, Aldhubiab B, et al. Development and evaluation of hydrogel-based sulfasalazine-loaded nanosponges for enhanced topical psoriasis therapy. Pharmaceuticals. 2025;18:391. https:\/\/doi.org\/10.3390\/ph18030391.","DOI":"10.3390\/ph18030391"},{"key":"3354_CR248","doi-asserted-by":"publisher","unstructured":"Thakur S, Anjum MM, Jaiswal S, Kumar A, Deepak P, Anand S, et al. Novel synergistic approach: tazarotene-calcipotriol-loaded-PVA\/PVP-nanofibers incorporated in hydrogel film for management and treatment of psoriasis. Mol Pharm. 2023;20:997\u20131014. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00713.","DOI":"10.1021\/acs.molpharmaceut.2c00713"},{"key":"3354_CR249","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1111\/bjd.15779","volume":"178","author":"JH Lee","year":"2018","unstructured":"Lee JH, Jung YS, Kim GM, Bae JM. A hyaluronic acid-based microneedle patch to treat psoriatic plaques: a pilot open trial. Br J Dermatol. 2018;178:e24-5. https:\/\/doi.org\/10.1111\/bjd.15779.","journal-title":"Br J Dermatol"},{"key":"3354_CR250","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120749","volume":"604","author":"L Zhang","year":"2021","unstructured":"Zhang L, Guo R, Wang S, Yang X, Ling G, Zhang P. Fabrication, evaluation and applications of dissolving microneedles. Int J Pharm. 2021;604:120749. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120749.","journal-title":"Int J Pharm"},{"key":"3354_CR251","doi-asserted-by":"publisher","unstructured":"Dai X, Permana AD, Li M, Habibie, Nur Amir M, Peng K, et al. Calcipotriol nanosuspension-loaded trilayer dissolving microneedle patches for the treatment of psoriasis: In Vitro Delivery and In Vivo Antipsoriatic Activity Studies. Mol Pharm Am Chem Soc. 2024;21:2813\u201327. \nhttps:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c01223.","DOI":"10.1021\/acs.molpharmaceut.3c01223"},{"key":"3354_CR252","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1021\/acsnano.2c08979","volume":"17","author":"D Bi","year":"2023","unstructured":"Bi D, Qu F, Xiao W, Wu J, Liu P, Du H, et al. Reactive oxygen species-responsive gel-based microneedle patches for prolonged and intelligent psoriasis management. ACS Nano. 2023;17:4346\u201357. https:\/\/doi.org\/10.1021\/acsnano.2c08979.","journal-title":"ACS Nano"},{"key":"3354_CR253","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4103\/0250-474X.40324","volume":"70","author":"S Rawat","year":"2008","unstructured":"Rawat S, Vengurlekar S, Rakesh B, Jain S, Srikarti G. Transdermal delivery by iontophoresis. Indian J Pharm Sci. 2008;70:5\u201310. https:\/\/doi.org\/10.4103\/0250-474X.40324.","journal-title":"Indian J Pharm Sci"},{"key":"3354_CR254","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/ajd.12029","volume":"54","author":"QV Le","year":"2013","unstructured":"Le QV, Howard A. Dexamethasone iontophoresis for the treatment of nail psoriasis. Australas J Dermatol. 2013;54:115\u20139. https:\/\/doi.org\/10.1111\/ajd.12029.","journal-title":"Australas J Dermatol"},{"key":"3354_CR255","doi-asserted-by":"publisher","first-page":"234","DOI":"10.4103\/2230-973X.93011","volume":"1","author":"R Prasad","year":"2011","unstructured":"Prasad R, Anand S, Koul V. Biophysical assessment of DC iontophoresis and current density on transdermal permeation of methotrexate. Int J Pharm Investig. 2011;1:234\u20139. https:\/\/doi.org\/10.4103\/2230-973X.93011.","journal-title":"Int J Pharm Investig"},{"key":"3354_CR256","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpolymj.2023.112630","volume":"202","author":"T Vasowala","year":"2024","unstructured":"Vasowala T, Gharat S, Mhase M, Momin M. Advances in hydrogels based cutaneous drug delivery system for management of psoriasis. Eur Polym J. 2024;202:112630. https:\/\/doi.org\/10.1016\/j.eurpolymj.2023.112630.","journal-title":"Eur Polym J"},{"key":"3354_CR257","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.1021\/acs.molpharmaceut.3c00729","volume":"20","author":"H Su","year":"2023","unstructured":"Su H, Liu Z, Zhang Z, Jing X, Meng L, American Chemical Society. Development of a deep eutectic solvent-assisted kaempferol hydrogel: a promising therapeutic approach for psoriasis-like skin inflammation. Mol Pharm. 2023;20:6319\u201329. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00729.","journal-title":"Mol Pharm"},{"key":"3354_CR258","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00449-024-03058-5","volume":"47","author":"DR Telange","year":"2024","unstructured":"Telange DR, Mahajan NM, Mandale T, More S, Warokar A. Pongamia pinnata seed extract-mediated green synthesis of silver nanoparticle loaded nanogel for estimation of their antipsoriatic properties. Bioprocess Biosyst Eng. 2024;47:1409\u201331. https:\/\/doi.org\/10.1007\/s00449-024-03058-5.","journal-title":"Bioprocess Biosyst Eng"},{"key":"3354_CR259","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/00914037.2017.1375493","volume":"67","author":"A Hemati Azandaryani","year":"2018","unstructured":"Hemati Azandaryani A, Derakhshandeh K, Arkan E, Taylor & Francis. Electrospun nanobandage for hydrocortisone topical delivery as an antipsoriasis candidate. Int J Polym Mater Polym Biomater. 2018;67:677\u201385. https:\/\/doi.org\/10.1080\/00914037.2017.1375493.","journal-title":"Int J Polym Mater Polym Biomater"},{"key":"3354_CR260","doi-asserted-by":"publisher","first-page":"41565","DOI":"10.1021\/acsomega.4c05346","volume":"9","author":"D Datta","year":"2024","unstructured":"Datta D, Bandi SP, Venuganti VVK, American Chemical Society. Ionic liquid-mediated transdermal delivery of organogel containing cyclosporine A for the effective treatment of psoriasis. ACS Omega. 2024;9:41565\u201382. https:\/\/doi.org\/10.1021\/acsomega.4c05346.","journal-title":"ACS Omega"},{"key":"3354_CR261","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s13346-024-01705-8","volume":"15","author":"Y Li","year":"2025","unstructured":"Li Y, Yu Q, Lu Y, Ma Y, Qi J, Chen Z, et al. Choline-based ionic liquids enhance the dermal delivery of cyclosporine a for potential treatment of psoriasis. Drug Deliv Transl Res. 2025;15:1693\u2013706. https:\/\/doi.org\/10.1007\/s13346-024-01705-8.","journal-title":"Drug Deliv Transl Res"},{"key":"3354_CR262","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2025.160972","volume":"508","author":"M Zeng","year":"2025","unstructured":"Zeng M, Deng P, Li Q, Tang Q, Li J, Zhang L. The H2S-releasing multifunctional composite ionic liquid facilitates topical melittin delivery for psoriasis treatment through RONS scavenging and inflammation inhibition. Chem Eng J. 2025;508:160972. https:\/\/doi.org\/10.1016\/j.cej.2025.160972.","journal-title":"Chem Eng J"},{"key":"3354_CR263","doi-asserted-by":"publisher","unstructured":"Mandal A, Kumbhojkar N, Reilly C, Dharamdasani V, Ukidve A, Ingber DE, et al. Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations. Sci Adv. 2020;6:eabb6049. https:\/\/doi.org\/10.1126\/sciadv.abb6049.","DOI":"10.1126\/sciadv.abb6049"},{"key":"3354_CR264","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jconrel.2023.12.009","volume":"365","author":"L Li","year":"2024","unstructured":"Li L, Wu X, Wu J, Zhang X, Miao F, Wang J, et al. Transdermal delivery of Fn14 siRNA using a novel composite ionic liquid for treatment of psoriasis-like skin lesions. J Control Release. 2024;365:818\u201332. https:\/\/doi.org\/10.1016\/j.jconrel.2023.12.009.","journal-title":"J Control Release"},{"key":"3354_CR265","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/bjd.20940","volume":"186","author":"A Luengas-Martinez","year":"2022","unstructured":"Luengas-Martinez A, Paus R, Young HS. A novel personalized treatment approach for psoriasis: anti-vascular endothelial growth factor-A (VEGF-A) therapy. Br J Dermatol. 2022;186:782\u201391. https:\/\/doi.org\/10.1111\/bjd.20940.","journal-title":"Br J Dermatol"},{"key":"3354_CR266","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108470","volume":"217","author":"R Castillo","year":"2020","unstructured":"Castillo R, Scher JU. Not your average joint: towards precision medicine in psoriatic arthritis. Clin Immunol. 2020;217:108470. https:\/\/doi.org\/10.1016\/j.clim.2020.108470.","journal-title":"Clin Immunol"},{"key":"3354_CR267","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000503141","volume":"66","author":"TM Doherty","year":"2020","unstructured":"Doherty TM, Di Pasquale A, Michel J-P, Del Giudice G. Precision medicine and vaccination of older adults: from reactive to proactive (A mini-review). Gerontology. 2020;66:238\u201348. https:\/\/doi.org\/10.1159\/000503141.","journal-title":"Gerontology"},{"key":"3354_CR268","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.alit.2020.06.001","volume":"69","author":"T Inomata","year":"2020","unstructured":"Inomata T, Sung J, Nakamura M, Fujisawa K, Muto K, Ebihara N, et al. New medical big data for P4 medicine on allergic conjunctivitis. Allergol Int. 2020;69:510\u20138. https:\/\/doi.org\/10.1016\/j.alit.2020.06.001.","journal-title":"Allergol Int"},{"key":"3354_CR269","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","volume":"143","author":"N Dand","year":"2019","unstructured":"Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143:2120\u201330. https:\/\/doi.org\/10.1016\/j.jaci.2018.11.038.","journal-title":"J Allergy Clin Immunol"},{"key":"3354_CR270","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jid.2018.07.028","volume":"139","author":"N Wilkinson","year":"2019","unstructured":"Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, et al. Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. J Invest Dermatol. 2019;139:115\u201323. https:\/\/doi.org\/10.1016\/j.jid.2018.07.028.","journal-title":"J Invest Dermatol"},{"key":"3354_CR271","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1001\/jamadermatol.2019.1783","volume":"155","author":"T Tsakok","year":"2019","unstructured":"Tsakok T, Wilson N, Dand N, Loeff FC, Bloem K, Baudry D, et al. Association of serum ustekinumab levels with clinical response in psoriasis. JAMA Dermatol. 2019;155:1235\u201343. https:\/\/doi.org\/10.1001\/jamadermatol.2019.1783.","journal-title":"JAMA Dermatol"},{"key":"3354_CR272","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2019-000273","volume":"4","author":"I Balikova","year":"2019","unstructured":"Balikova I, Postelmans L, Pasteels B, Coquelet P, Catherine J, Efendic A, et al. Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degeneration. BMJ Open Ophthalmol. 2019;4:e000273. https:\/\/doi.org\/10.1136\/bmjophth-2019-000273.","journal-title":"BMJ Open Ophthalmol"},{"key":"3354_CR273","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1136\/bjophthalmol-2016-308388","volume":"100","author":"M Ashraf","year":"2016","unstructured":"Ashraf M, Souka A, Adelman R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. Br J Ophthalmol. 2016;100:1596\u2013604. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-308388.","journal-title":"Br J Ophthalmol"},{"key":"3354_CR274","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/sj.jid.5700096","volume":"126","author":"HS Young","year":"2006","unstructured":"Young HS, Summers AM, Read IR, Fairhurst DA, Plant DJ, Campalani E, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol. 2006;126:453\u20139. https:\/\/doi.org\/10.1038\/sj.jid.5700096.","journal-title":"J Invest Dermatol"},{"key":"3354_CR275","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335\u201342. https:\/\/doi.org\/10.1056\/NEJMoa032691.","journal-title":"N Engl J Med"},{"key":"3354_CR276","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15\u00a0years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102017.","journal-title":"Cancer Treat Rev"},{"key":"3354_CR277","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1080\/14712598.2021.1830969","volume":"20","author":"DSC Ng","year":"2020","unstructured":"Ng DSC, Fung NSK, Yip FLT, Lai TYY. Ranibizumab for myopic choroidal neovascularization. Expert Opin Biol Ther. 2020;20:1385\u201393. https:\/\/doi.org\/10.1080\/14712598.2021.1830969.","journal-title":"Expert Opin Biol Ther"},{"key":"3354_CR278","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40265-020-01263-6","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Ramucirumab: a review in hepatocellular carcinoma. Drugs. 2020;80:315\u201322. https:\/\/doi.org\/10.1007\/s40265-020-01263-6.","journal-title":"Drugs"},{"key":"3354_CR279","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/14737140.2019.1559058","volume":"19","author":"B Escudier","year":"2019","unstructured":"Escudier B, Worden F, Kudo M. Sorafenib: key lessons from over 10 years of experience. Expert Rev Anticancer Ther. 2019;19:177\u201389. https:\/\/doi.org\/10.1080\/14737140.2019.1559058.","journal-title":"Expert Rev Anticancer Ther"},{"key":"3354_CR280","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.101993","volume":"86","author":"A Grothey","year":"2020","unstructured":"Grothey A, Blay J-Y, Pavlakis N, Yoshino T, Bruix J. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treat Rev. 2020;86:101993. https:\/\/doi.org\/10.1016\/j.ctrv.2020.101993.","journal-title":"Cancer Treat Rev"},{"key":"3354_CR281","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2174\/0929867324666171006165942","volume":"26","author":"SM Ferrari","year":"2019","unstructured":"Ferrari SM, Centanni M, Virili C, Miccoli M, Ferrari P, Ruffilli I, et al. Sunitinib in the treatment of thyroid cancer. Curr Med Chem. 2019;26:963\u201372. https:\/\/doi.org\/10.2174\/0929867324666171006165942.","journal-title":"Curr Med Chem"},{"key":"3354_CR282","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1210\/er.2019-00007","volume":"40","author":"ME Cabanillas","year":"2019","unstructured":"Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev. 2019;40:1573\u2013604. https:\/\/doi.org\/10.1210\/er.2019-00007.","journal-title":"Endocr Rev"},{"key":"3354_CR283","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","volume":"15","author":"N Ferrara","year":"2016","unstructured":"Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385\u2013403. https:\/\/doi.org\/10.1038\/nrd.2015.17.","journal-title":"Nat Rev Drug Discov"},{"key":"3354_CR284","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","volume":"17","author":"NS Vasudev","year":"2014","unstructured":"Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17:471\u201394. https:\/\/doi.org\/10.1007\/s10456-014-9420-y.","journal-title":"Angiogenesis"},{"key":"3354_CR285","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejphar.2018.01.048","volume":"824","author":"Y-H Kuang","year":"2018","unstructured":"Kuang Y-H, Lu Y, Liu Y-K, Liao L-Q, Zhou X-C, Qin Q-S, et al. Topical sunitinib ointment alleviates psoriasis-like inflammation by inhibiting the proliferation and apoptosis of keratinocytes. Eur J Pharmacol. 2018;824:57\u201363. https:\/\/doi.org\/10.1016\/j.ejphar.2018.01.048.","journal-title":"Eur J Pharmacol"},{"key":"3354_CR286","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jphs.2015.05.008","volume":"128","author":"J Wen","year":"2015","unstructured":"Wen J, Wang X, Pei H, Xie C, Qiu N, Li S, et al. Anti-psoriatic effects of Honokiol through the inhibition of NF-\u03baB and VEGFR-2 in animal model of K14-VEGF transgenic mouse. J Pharmacol Sci. 2015;128:116\u201324. https:\/\/doi.org\/10.1016\/j.jphs.2015.05.008.","journal-title":"J Pharmacol Sci"},{"key":"3354_CR287","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1111\/j.1365-2230.2008.02991.x","volume":"34","author":"A Akman","year":"2009","unstructured":"Akman A, Yilmaz E, Mutlu H, Ozdogan M. Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol. 2009;34:e202-204. https:\/\/doi.org\/10.1111\/j.1365-2230.2008.02991.x.","journal-title":"Clin Exp Dermatol"},{"key":"3354_CR288","doi-asserted-by":"publisher","first-page":"632","DOI":"10.4103\/0019-5154.143574","volume":"59","author":"A Datta-Mitra","year":"2014","unstructured":"Datta-Mitra A, Riar NK, Raychaudhuri SP. Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer. Indian J Dermatol. 2014;59:632. https:\/\/doi.org\/10.4103\/0019-5154.143574.","journal-title":"Indian J Dermatol"},{"key":"3354_CR289","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000508344","volume":"33","author":"A Luengas-Martinez","year":"2020","unstructured":"Luengas-Martinez A, Hardman-Smart J, Rutkowski D, Purba TS, Paus R, Young HS. Vascular endothelial growth factor blockade induces dermal endothelial cell apoptosis in a clinically relevant skin organ culture model. Skin Pharmacol Physiol. 2020;33:110\u20138. https:\/\/doi.org\/10.1159\/000508344.","journal-title":"Skin Pharmacol Physiol"},{"key":"3354_CR290","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.trsl.2007.01.003","volume":"149","author":"M Keshtgarpour","year":"2007","unstructured":"Keshtgarpour M, Dudek AZ. SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Transl Res. 2007;149:103\u20136. https:\/\/doi.org\/10.1016\/j.trsl.2007.01.003.","journal-title":"Transl Res"},{"key":"3354_CR291","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/MAJ.0b013e3181dd1aa5","volume":"339","author":"S Narayanan","year":"2010","unstructured":"Narayanan S, Callis-Duffin K, Batten J, Agarwal N. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci. 2010;339:580\u20131. https:\/\/doi.org\/10.1097\/MAJ.0b013e3181dd1aa5.","journal-title":"Am J Med Sci"},{"key":"3354_CR292","doi-asserted-by":"publisher","DOI":"10.5070\/D32Z47H80W","volume":"16","author":"C Fournier","year":"2010","unstructured":"Fournier C, Tisman G. Sorafenib-associated remission of psoriasis in hypernephroma: case report. Dermatol Online J. 2010;16:17.","journal-title":"Dermatol Online J"},{"key":"3354_CR293","first-page":"677","volume":"30","author":"EA Antoniou","year":"2016","unstructured":"Antoniou EA, Koutsounas I, Damaskos C, Koutsounas S. Remission of psoriasis in a patient with hepatocellular carcinoma treated with sorafenib. In Vivo. 2016;30:677\u201380.","journal-title":"In Vivo"},{"key":"3354_CR294","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jdcr.2018.09.009","volume":"4","author":"MS van Kester","year":"2018","unstructured":"van Kester MS, Luelmo SAC, Vermeer MH, Blank C, van Doorn R. Remission of psoriasis during treatment with sorafenib. JAAD Case Rep. 2018;4:1065\u20137. https:\/\/doi.org\/10.1016\/j.jdcr.2018.09.009.","journal-title":"JAAD Case Rep"},{"key":"3354_CR295","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1067\/mjd.2002.124702","volume":"47","author":"DN Sauder","year":"2002","unstructured":"Sauder DN, Dekoven J, Champagne P, Croteau D, Dupont E. Neovastat (AE-941), an inhibitor of angiogenesis: randomized phase I\/II clinical trial results in patients with plaque psoriasis. J Am Acad Dermatol. 2002;47:535\u201341. https:\/\/doi.org\/10.1067\/mjd.2002.124702.","journal-title":"J Am Acad Dermatol"},{"key":"3354_CR296","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1586\/14737140.1.3.341","volume":"1","author":"D Gingras","year":"2001","unstructured":"Gingras D, Batist G, B\u00e9liveau R. <article-title update=\"added\"> \u00c6-941 (Neovastat \u00ae ): a novel multifunctional antiangiogenic compound. Expert Rev Anticancer Ther. 2001;1:341\u20137. https:\/\/doi.org\/10.1586\/14737140.1.3.341.","journal-title":"Expert Rev Anticancer Ther"},{"key":"3354_CR297","first-page":"1242","volume":"8","author":"R B\u00e9liveau","year":"2002","unstructured":"B\u00e9liveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, et al. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin Cancer Res. 2002;8:1242\u201350.","journal-title":"Clin Cancer Res"},{"key":"3354_CR298","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s10227-002-0120-7","volume":"7","author":"E Dupont","year":"2003","unstructured":"Dupont E, Wang B, Mamelak AJ, Howell BG, Shivji G, Zhuang L, et al. Modulation of the contact hypersensitivity response by AE-941 (Neovastat), a novel antiangiogenic agent. J Cutan Med Surg. 2003;7:208\u201316. https:\/\/doi.org\/10.1007\/s10227-002-0120-7.","journal-title":"J Cutan Med Surg"},{"key":"3354_CR299","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115504","volume":"217","author":"T Auel","year":"2025","unstructured":"Auel T, Mentrup AFC, Oldfield LR, Seidlitz A. 3D printing of pharmaceutical dosage forms: recent advances and applications. Adv Drug Deliv Rev. 2025;217:115504. https:\/\/doi.org\/10.1016\/j.addr.2024.115504.","journal-title":"Adv Drug Deliv Rev"},{"key":"3354_CR300","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2024.114523","volume":"204","author":"LC P\u00fcnnel","year":"2024","unstructured":"P\u00fcnnel LC, Palmtag M, Lunter DJ, Perry JL. Development of 3D printed microneedles of varied needle geometries and lengths, designed to improve the dermal delivery of topically applied psoriasis treatments. Eur J Pharm Biopharm. 2024;204:114523. https:\/\/doi.org\/10.1016\/j.ejpb.2024.114523.","journal-title":"Eur J Pharm Biopharm"},{"key":"3354_CR301","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1039\/d3tb02643d","volume":"12","author":"H Du","year":"2024","unstructured":"Du H, Yang J, Li M, Xia Y, Li Y, Zhu J, et al. Microneedle-assisted percutaneous delivery of methotrexate-loaded nanoparticles enabling sustained anti-inflammatory effects in psoriasis therapy. J Mater Chem B. 2024;12:2618\u201327. https:\/\/doi.org\/10.1039\/d3tb02643d.","journal-title":"J Mater Chem B"},{"key":"3354_CR302","doi-asserted-by":"publisher","DOI":"10.1038\/srep21422","volume":"6","author":"Y Deng","year":"2016","unstructured":"Deng Y, Chen J, Zhao Y, Yan X, Zhang L, Choy K, et al. Transdermal delivery of siRNA through microneedle array. Sci Rep. 2016;6:21422. https:\/\/doi.org\/10.1038\/srep21422.","journal-title":"Sci Rep"},{"key":"3354_CR303","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1021\/jacsau.2c00432","volume":"2","author":"NU Rajesh","year":"2022","unstructured":"Rajesh NU, Coates I, Driskill MM, Dulay MT, Hsiao K, Ilyin D, et al. 3D-printed microarray patches for transdermal applications. JACS Au. 2022;2:2426\u201345. https:\/\/doi.org\/10.1021\/jacsau.2c00432.","journal-title":"JACS Au"},{"key":"3354_CR304","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01852-x","volume":"9","author":"P Lu","year":"2024","unstructured":"Lu P, Ruan D, Huang M, Tian M, Zhu K, Gan Z, et al. Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions. Signal Transduct Target Ther. 2024;9:166. https:\/\/doi.org\/10.1038\/s41392-024-01852-x.","journal-title":"Signal Transduct Target Ther"},{"key":"3354_CR305","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03055-4","volume":"316","author":"M Bicer","year":"2024","unstructured":"Bicer M. Revolutionizing dermatology: harnessing mesenchymal stem\/stromal cells and exosomes in 3D platform for skin regeneration. Arch Dermatol Res. 2024;316:242. https:\/\/doi.org\/10.1007\/s00403-024-03055-4.","journal-title":"Arch Dermatol Res"},{"key":"3354_CR306","unstructured":"de Oliveira Barros R. 3D Printing-Based Technology Using Mesenchymal Stem Cells for Personalized Psoriasis Therapy. Universidade de Lisboa (Portugal); 2020."},{"key":"3354_CR307","doi-asserted-by":"publisher","DOI":"10.1016\/j.nexres.2025.100731","volume":"2","author":"A Gupta","year":"2025","unstructured":"Gupta A, Gupta SK. Interplay of novel formulation-based treatment strategies for psoriasis: advancing therapeutic outcomes. Next Research. 2025;2:100731. https:\/\/doi.org\/10.1016\/j.nexres.2025.100731.","journal-title":"Next Research"},{"key":"3354_CR308","unstructured":"Hassen R. Treatment of psoriasis. 2024 [cited 2025 Nov 30]. https:\/\/patents.google.com\/patent\/WO2024252238A1\/en. Accessed 30 Nov 2025."},{"key":"3354_CR309","unstructured":"Mutalik S, Mullick P. Anti-psoriasis topical formulation containing combination drugs and method of preparation thereof. 2024 [cited 2025 Nov 30]. https:\/\/patents.google.com\/patent\/WO2024201481A1\/en. Accessed 30 Nov 2025."},{"key":"3354_CR310","unstructured":"Zheng B, Guo Q, Cao Y, Cheng S, Bai Z. Transdermal double-layer microneedle based on hydrogen producing probiotics and its preparation method and application. 2024 [cited 2025 Nov 30]. https:\/\/patents.google.com\/patent\/US20240091514A1\/en?oq=US20240091514. Accessed 30 Nov 2025."},{"key":"3354_CR311","unstructured":"Petersson K, Engell KM, Jansson J, Nielsen KT, Eriksson AH, Moore A, et al. Microneedle patch for delivering an active ingredient to skin. 2016 [cited 2025 Nov 30]. https:\/\/patents.google.com\/patent\/WO2016155891A1\/de. Accessed 30 Nov 2025."},{"key":"3354_CR312","unstructured":"Changoer L, Anastassov G. Method to treat psoriasis. 2019 [cited 2025 Nov 30]. https:\/\/patents.google.com\/patent\/US20190060250A1\/en. Accessed 30 Nov 2025."},{"key":"3354_CR313","unstructured":"Chen G, Webster JM, Li J, Hu K, Liu W, Zhu J. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues. 2008 [cited 2025 Nov 29]. https:\/\/patents.google.com\/patent\/US7321050B2\/en. Accessed 29 Nov 2025."},{"key":"3354_CR314","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","volume":"380","author":"K Papp","year":"2012","unstructured":"Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380:738\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(12)60642-4.","journal-title":"Lancet"},{"key":"3354_CR315","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/jdv.13918","volume":"31","author":"D Tha\u00e7i","year":"2017","unstructured":"Tha\u00e7i D, Kimball A, Foley P, Poulin Y, Levi E, Chen R, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. J Eur Acad Dermatol Venereol. 2017;31:498\u2013506. https:\/\/doi.org\/10.1111\/jdv.13918.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3354_CR316","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/jdv.14738","volume":"32","author":"K Reich","year":"2018","unstructured":"Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol. 2018;32:397\u2013402. https:\/\/doi.org\/10.1111\/jdv.14738.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3354_CR317","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2000073","volume":"383","author":"MG Lebwohl","year":"2020","unstructured":"Lebwohl MG, Papp KA, Stein Gold L, Gooderham MJ, Kircik LH, Draelos ZD, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383:229\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2000073.","journal-title":"N Engl J Med"},{"key":"3354_CR318","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2022.15632","volume":"328","author":"MG Lebwohl","year":"2022","unstructured":"Lebwohl MG, Kircik LH, Moore AY, Stein Gold L, Draelos ZD, Gooderham MJ, et al. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials. JAMA. 2022;328:1073\u201384. https:\/\/doi.org\/10.1001\/jama.2022.15632.","journal-title":"JAMA"},{"key":"3354_CR319","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jaad.2024.03.030","volume":"91","author":"L Stein Gold","year":"2024","unstructured":"Stein Gold L, Adam DN, Albrecht L, Alonso-Llamazares J, Ferris LK, Gooderham MJ, et al. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: a 52-week, phase 2, open-label trial. J Am Acad Dermatol. 2024;91:273\u201380. https:\/\/doi.org\/10.1016\/j.jaad.2024.03.030.","journal-title":"J Am Acad Dermatol"},{"key":"3354_CR320","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PDR, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693\u2013700. https:\/\/doi.org\/10.1136\/gutjnl-2011-301668.","journal-title":"Gut"},{"key":"3354_CR321","doi-asserted-by":"publisher","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, et al. Secukinumab in Plaque Psoriasis \u2014 Results of Two Phase 3 Trials. N Engl J Med. 2014;371:326\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1314258.","DOI":"10.1056\/NEJMoa1314258"},{"key":"3354_CR322","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, Crowley JJ, Ryan C, Krueger JG, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394:576\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(19)30952-3.","journal-title":"Lancet"},{"key":"3354_CR323","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s13671-024-00434-y","volume":"13","author":"P Smith","year":"2024","unstructured":"Smith P, Johnson CE, Haran K, Orcales F, Kranyak A, Bhutani T, et al. Advancing Psoriasis Care through Artificial Intelligence: a comprehensive review. Curr Dermatol Rep. 2024;13:141\u20137. https:\/\/doi.org\/10.1007\/s13671-024-00434-y.","journal-title":"Curr Dermatol Rep"},{"key":"3354_CR324","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59954","volume":"16","author":"D Dixon","year":"2024","unstructured":"Dixon D, Sattar H, Moros N, Kesireddy SR, Ahsan H, Lakkimsetti M, et al. Unveiling the influence of AI predictive analytics on patient outcomes: a comprehensive narrative review. Cureus. 2024;16:e59954. https:\/\/doi.org\/10.7759\/cureus.59954.","journal-title":"Cureus"},{"key":"3354_CR325","doi-asserted-by":"publisher","DOI":"10.1007\/s10462-024-11031-7","volume":"58","author":"M Ghorbian","year":"2024","unstructured":"Ghorbian M, Ghobaei-Arani M, Ghorbian S. A comprehensive study on the application of machine learning in psoriasis diagnosis and treatment: taxonomy, challenges and recommendations. Artif Intell Rev. 2024;58:60. https:\/\/doi.org\/10.1007\/s10462-024-11031-7.","journal-title":"Artif Intell Rev"},{"key":"3354_CR326","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/jdv.17711","volume":"36","author":"MJ Schaap","year":"2022","unstructured":"Schaap MJ, Cardozo NJ, Patel A, de Jong EMGJ, van Ginneken B, Seyger MMB. Image\u2010based automated Psoriasis Area Severity Index scoring by Convolutional Neural Networks. J Eur Acad Dermatol Venereol. 2022;36:68\u201375. https:\/\/doi.org\/10.1111\/jdv.17711.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3354_CR327","doi-asserted-by":"publisher","DOI":"10.1186\/s12909-023-04698-z","volume":"23","author":"SA Alowais","year":"2023","unstructured":"Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Med Educ. 2023;23:689. https:\/\/doi.org\/10.1186\/s12909-023-04698-z.","journal-title":"BMC Med Educ"},{"key":"3354_CR328","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125789","volume":"680","author":"SJ Jarallah","year":"2025","unstructured":"Jarallah SJ, Almughem FA, Alhumaid NK, Fayez NA, Alradwan I, Alsulami KA, et al. Artificial intelligence revolution in drug discovery: a paradigm shift in pharmaceutical innovation. Int J Pharm. 2025;680:125789. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125789.","journal-title":"Int J Pharm"},{"key":"3354_CR329","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.tips.2023.04.005","volume":"44","author":"P Moingeon","year":"2023","unstructured":"Moingeon P. Artificial intelligence-driven drug development against autoimmune diseases. Trends Pharmacol Sci. 2023;44:411\u201324. https:\/\/doi.org\/10.1016\/j.tips.2023.04.005.","journal-title":"Trends Pharmacol Sci"},{"key":"3354_CR330","doi-asserted-by":"publisher","DOI":"10.1016\/j.artmed.2024.103000","volume":"157","author":"V Tandel","year":"2024","unstructured":"Tandel V, Kumari A, Tanwar S, Singh A, Sharma R, Yamsani N. Intelligent wearable-assisted digital healthcare industry 5.0. Artif Intell Med. 2024;157:103000. https:\/\/doi.org\/10.1016\/j.artmed.2024.103000.","journal-title":"Artif Intell Med"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03354-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:50:33Z","timestamp":1780390233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03354-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":330,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["3354"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03354-1","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (review article).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors report there are no conflict of interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"137"}}